0001579010
false
0001579010
2022-09-15
2022-09-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September
15, 2022
LIFE ON EARTH, INC.
(Exact name of registrant
as specified in its charter)
Delaware
(State or other
jurisdiction of incorporation) |
|
000-55464
(Commission
File Number) |
|
46-2552550
(I.R.S. Employer
Identification No.) |
1270 N. Wickham Road, Suite 13, No. 1019
Melbourne, FL
(Address of principal executive offices) |
|
32935
(Zip Code) |
Registrant’s telephone number, including
area code: (321) 306-0306
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: |
|
|
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
None |
|
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Section 1 - Registrant’s
Business and Operations
Item 1.02 Termination
of a Material Definitive Agreement
On December 31, 2021, Registrant entered into a Management
Operating Agreement with CareClix Holdings, Inc. (“SOLI”) which enabled Registrant to complete a provisional closing (the
“Interim Closing”) of the acquisition of four operating subsidiaries of SOLI, with the final closing of the transaction to
occur when a Form S-4 registration statement to register the consideration shares to be issued by Registrant, was filed by Registrant
with and declared effective by the SEC, but by no later than May 31, 2022. As part of the Interim Closing, Charles Scott and Dr. John
Korangy were appointed to Registrant’s Board of Directors. If the registration statement was not declared effective by May 31, 2022,
then the transaction failed, the Interim Closing became void, the CareClix subsidiaries again became subsidiaries of SOLI, and the mutual
release in the event of termination of the proposed transaction became effective. In April 2022, as a result of disagreements between
management of the CareClix subsidiaries and the now former management of Registrant (Mahmood Khan, John C. Romagosa, Robert Gunther and
Fernando Leonzo (collectively the “Former Management”)) ,and the multiple defaults by Registrant in meeting the terms and
conditions of the Stock Purchase Agreement of December 17, 2021 and the Management Operating Agreement as set forth in part in the Form
10-Q for the quarter ended February 28, 2022 as filed with the SEC, SOLI formally offered the option to Former Management to rescind and
terminate the Interim Closing on multiple occasions. Former Management refused these offers but continued to refuse to cure the defaults
by Registrant.
To undertake to cure the
continuing defaults and also to initiate the audits of the CareClix subsidiaries by Registrant as required by the Management Operating
Agreement, on April 26, 2022, acting as majority voting shareholder of Registrant, Charles O. Scott voted
to remove Fernando Leonzo and John C. Romagosa as directors and officers of Registrant. On April 29, 2022, again acting as majority voting
shareholder of Registrant, Charles O. Scott voted to remove Mahmood Kahn and Robert Gunther as directors and officers of Registrant. The
removals were done in compliance with Section 141(k) of the Delaware General Corporation Law. These removals left Charles Scott and Dr.
John Korangy as the remaining members of the Registrant’s Board of Directors.:
On May 2, 2022, the Board
of Directors of Registrant approved an Amended Management Operating Agreement, removing all further conditions to the Final Closing except
the obligation by Registrant to register and issue the balance of the common share consideration, and removing the automatic termination
provision in the event that certain conditions were not met by May 31, 2022. The share consideration, a total
of 300 million shares of Registrant’s common stock, were reserved for issuance as soon as the shares are registered on Form S-4,
and the remainder of the 4,000,000 shares of Registrant’s Series A Preferred stock, which votes with the common stock at 60 votes
per Series A Preferred share, were issued to Charles O. Scott, former control shareholder of SOLI, and 1,200,000 shares of Series A Preferred
previously held by Former Management, were cancelled and reissued to Mr. Scott, as agreed.
On September 9, 2022, Former Management of Registrant
filed a purported derivative action against Registrant and its purported Board of Directors, in the Court of Chancery of the State of
Delaware, seeking:
| 1. | A declaration that their removal as directors and officers was not valid; |
| 2. | Unspecified damages for “intentional mismanagement” by declaring
the Interim Closing of the CareClix acquisition as the Final Closing and seeking to rescind the acquisition transaction. |
Immediately on learning of the action filed by Former
Management, Registrant’s Board of Directors immediately rescinded the Board action on May 2, 2022 approving the Amended Management
Operating Agreement, resulting in a default of the Interim Closing of the proposed acquisition of the CareClix companies for failure of
consideration and failure by Registrant to register the common share consideration by May 31, 2022. Consequently,
ownership of the CareClix companies reverted to SOLI
effective May 31, 2022, Registrant and SOLI have severed all remaining connection except for a promissory note by Registrant in favor
of CareClix for $128,432 in funds voluntarily advanced to or for Registrant for payment of Registrant operating expenses from December
1, 2021 through September, 2022, and the mutual release of claims contained in the Share Purchase Agreement became effective. The Share
Purchase Agreement did not contain any early or other termination penalty on any party and an arbitration provision in both the Share
Purchase Agreement and the Management Operating Agreement survived termination and controls any future issues between the parties.
Section 5 - Corporate Governance and Management
Item 5.01 Changes in Control
of Registrant.
As a result
of the default by Registrant in the acquisition transaction referenced in Item 1.02, Charles O. Scott remained as the majority voting
shareholder of Registrant, holding 5,200,000 shares of Series A Preferred stock, with 312,000,000 total votes, resulting in voting control
as follows:
|
|
Issued |
|
Vote |
|
Percent |
|
|
Common |
|
|
71,822,753 |
|
|
|
71,822,753 |
|
|
|
18.7 |
|
|
|
Preferred A |
|
|
5,200,000 |
|
|
|
312,000,000 |
|
|
|
81.3 |
|
|
|
Preferred B |
|
|
100,000 |
|
|
|
0 |
|
|
|
0 |
|
|
|
Preferred C |
|
|
2,613,375 |
|
|
|
0 |
|
|
|
0 |
|
|
|
Preferred D |
|
|
16,236 |
|
|
|
0 |
|
|
|
0 |
|
|
|
Since the
shares of Series A Preferred stock held by Mr. Scott were part of the consideration for the proposed acquisition of the CareClix companies
by Registrant, which transaction has failed, Mr. Scott conveyed the Series A Preferred stock to Registrant for cancellation. The Series
A shares all have been cancelled and currently there are no Series A shares issued or outstanding. As a result, the current voting control
of Registrant will be based solely on the common stock, as to which no shareholder or group holds voting control of Registrant. The current
major common shareholders are:
Name of beneficial owner |
|
Amount of
beneficial ownership |
|
Percent of class |
Fernando Leonzo, Former Director & Officer |
|
|
4,517,726 |
|
|
|
6.29 |
Robert Gunther, Former Director & Officer |
|
|
3,513,458 |
|
|
|
4.89 |
John Romagosa, Former Director & Officer |
|
|
6,318,738 |
|
|
|
8.80 |
Mahmood Khan, Former Director & Officer |
|
|
9,476,490 |
|
|
|
13.19 |
Shircoo, Inc. |
|
|
14,084,334 |
|
|
|
19.61 |
Item 5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective
with the filing of this Current Report on Form 8-K with the SEC, Charles Scott and Dr. John Korangy have submitted their resignations
as directors and officers of Registrant and Jeffry Hollis has submitted his resignation as Controller of Registrant. The resignations
are the result of the action filed by the Former Management seeking to recover their former positions with Registrant and to terminate
the pending acquisition of the CareClix companies. Mr. Scott and Dr. Korangy have not appointed one or more successor directors or officers
as they have no equity or other interest in Registrant, the Former Management is currently suing Registrant, and there are concerns regarding
the conduct of Former Management before their termination, all of which indicate that new directors should appropriately be elected by
the common shareholders at a Special Meeting of Shareholders.
None of
Mr. Scott, Dr. Korangy or Mr. Hollis, and no other person or consultant affiliated with the CareClix companies, is a shareholder of Registrant,
or has earned, received, or been entitled to any compensation from Registrant. All of the resigning directors and officers have been furnished
with a copy of this disclosure by Registrant and all have expressed no need to respond to these disclosures.
Section 8 - Other Events
Item 8.01 Other Events.
As noted in Item 1.02 above, on September 9, 2022,
Registrant’s Former Management filed an action against Registrant, Charles Scott and Dr. John Korangy as directors of Registrant,
and against an independent consultant erroneously alleged to be a director of Registrant, seeking to rescind the acquisition of the CareClix
companies by Registrant. Registrant’s fiscal year ended May 31, 2022 and an Annual Report on Form 10-K was required to be filed
in 90 days, or on or before August 29, 2022. Following termination of the Former Management on April 26 and April 29, 2022, Registrant’s
remaining directors, Mr. Scott and Dr. Korangy, initiated for the first time, the audit of the books of Registrant and the preparation
of the Annual Report on Form 10-K, but were hampered in their efforts by the failure and refusal of Former Management to turn over corporate
records, documents and information needed for the audit and Annual Report, despite requests to do so. On August 29, 2022, Registrant filed
a Notice of Late Filing with the SEC, indicating the Annual Report would be filed within 15 days of the due date, or by September 13,
2022. The Form 10-K and audited financial statements to be included in the Form 10-K were prepared by Registrant on the basis of a completed
Final Closing of the CareClix acquisition as of May 2, 2022 and included discussion of management plans and analysis of Registrant’s
operations with the CareClix companies included. As a result of the lawsuit filed by Former Management against Registrant and its directors
on September 9, 2022, and the rescission and cancellation of
the Amended Management Operating Agreement, the CareClix acquisition terminated
as of May 31, 2021, and it was no longer appropriate to file the Annual Report on Form 10-K including, as it did, references and details
of the CareClix companies as the basis for Registrant to continue as a going concern. Accordingly, Registrant revised the Form 10-K to
remove all references to the CareClix companies as part of the on-going consolidated operations of Registrant and engaged an independent
audit firm to restate the audit to include only Registrant. Registrant owes the independent audit firm $25,000 for prior work unrelated
to the current Annual Report and will owe additional amounts, to be determined, for the audit to be included in the current Annual Report
and has had difficulty contacting the independent audit firm. Given the current resignations of Registrant’s directors and officers,
filing of the revised Form 10-K including only Registrant, which has been ready for filing except for the final audit opinion letter,
has been postponed pending, election of directors by the common shareholders of Registrant and appointment by them of new officers. A
copy of the revised unaudited Form 10-K in final EDGAR format is attached as Exhibit 13
9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits
|
(a) |
Financial statements of businesses acquired. |
The Final Closing of the acquisition of the CareClix subsidiaries
was terminated effective May 31, 2022. Required audited financial statements of the CareClix subsidiaries accordingly will notnot be filed
by an amendment to the Form 8-K Current Report filed May 6, 2022 and are not attached as an Exhibit to this Report.
|
(b) |
Pro forma financial information |
(c) Shell company transactions
(d) Exhibits)
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 6, 2022 |
Life On Earth, Inc. |
|
|
|
|
|
|
By: |
/s/ Charles O. Scott |
|
|
Name: |
Charles O. Scott |
|
|
Title: |
Chairman and Chief Executive Officer |
|
Exhibit 10.1
Mutual Release
Please refer to the accompanying Exhibit 10.1. It is saved in PDF format.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_________________
FORM 10-K
☒ ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended: May 31, 2022
OR
☐ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _________________ to
______________________
Commission file number: 001-34673
LIFE ON EARTH, INC. |
(Exact name of Registrant as Specified in Its Charter) |
Delaware |
|
46-2552550 |
(State or Other Jurisdiction of Incorporation or Organization) |
|
(I.R.S. Employer Identification No.) |
1270 N. Wickham Road, #13A-1019, Melbourne, FL |
|
32935 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (833) 516-0606
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Name of each exchange on which registered |
Common Stock, $0.001 Par Value |
|
OTC QB |
Securities registered pursuant to Section 12(g) of the Act: None
Title of each class |
|
Trading Symbol |
|
Name of exchange on which registered |
COMMON STOCK, $0.001 par value per share |
|
LFER |
|
OTC QB |
Indicate by check mark if the registrant
is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant
is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days
Yes ☒
No ☐
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding
12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark if disclosure of delinquent
filers pursuant to Item 405 of Regulations S-K is not contained herein, and will not be contained, to the best of the registrant’s
knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. ☐
Indicate by check mark whether the registrant is a large accelerated filer,
an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large
accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company”
in Rule 12b-2 of the Exchange Act: ☐
Large accelerated filer |
¨ |
Accelerated filer |
¨ |
Non-accelerated Filer |
¨ |
Smaller reporting company |
x |
|
|
Emerging growth company |
x |
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any news or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
The aggregate market value of the registrant’s
voting common equity held by non-affiliates of the registrant, based upon the closing price of the registrant’s common stock on
the last business day of the registrant’s most recently completed second fiscal quarter (November 30, 2021) was approximately $3,762,551.
The number of issued shares of the registrant’s
common stock was 71,822,753 shares at September 23, 2022.
DOCUMENTS INCORPORATED BY REFERENCE
None.
TABLE OF CONTENTS
|
|
|
Page |
|
Forward Looking Statements |
|
1 |
|
|
|
|
PART I |
|
|
|
|
Item 1. |
Business |
|
1 |
|
Item 1A . |
Risk Factors |
|
35 |
|
Item 1B. |
Unresolved Staff Comments |
|
3 |
|
Item 2. |
Properties |
|
3 |
|
Item 3. |
Legal Proceedings |
|
4 |
|
Item 4. |
Mine Safety Disclosures |
|
4 |
|
|
|
|
|
|
PART II |
|
|
|
|
Item 5. |
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |
|
4 |
|
Item 6. |
Selected Financial Data |
|
5 |
|
Item 7. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|
6 |
|
Item 7A . |
Quantitative and Qualitative Disclosures About Market Risk |
|
8 |
|
Item 8. |
Financial Statements and Supplementary Data |
|
8 |
|
Item 9. |
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure |
|
8 |
|
Item 9A. |
Controls and Procedures |
|
8 |
|
Item 9B. |
Other Information |
|
9 |
|
|
|
|
|
|
PART III |
|
|
|
|
Item 10. |
Directors, Executive Officers and Corporate Governance |
|
10 |
|
Item 11. |
Executive Compensation |
|
11 |
|
Item 12. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
|
13 |
|
Item 13. |
Certain Relationships and Related Transactions, and Director Independence |
|
14 |
|
Item 14. |
Principal Accountant Fees and Services |
|
15 |
|
|
|
|
|
|
PART IV |
|
|
|
|
Item 15. |
Exhibits, Financial Statement Schedules |
|
16 |
|
|
|
|
|
|
SIGNATURES |
|
16 |
|
FORWARD - LOOKING STATEMENTS
This Annual Report on Form 10-K (Report) certain
forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933,
as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) that reflect management’s current views and expectations with respect to our business, strategies, products,
future results and events, and financial performance. All statements made in this Report other than statements of historical fact, including
statements that address operating performance, the economy, events or developments that management expects or anticipates will or may
occur in the future, including statements related to sales, revenues, profitability, distributor channels, new products, adequacy of funds
from operations, cash flows and financing, our ability to continue as a going concern, potential strategic transactions, statements regarding
future operating results and non-historical information, are forward-looking statements. In particular, the words such as “believe,”
“expect,” “intend, ”anticipate,” “estimate,” “may,” “will,” “can,”
“plan,” “predict,” “could,” “future,” “continue,” variations of such words,
and similar expressions identify forward-looking statements, but are not the exclusive means of identifying such statements and their
absence does not mean that the statement is not forward-looking. Readers should not place undue reliance on these forward-looking statements,
which are based on management’s current expectations and projections about future events, are not guarantees of future performance,
are subject to risks, uncertainties and assumptions and apply only as of the date of this Report. Our actual results, performance or achievements
could differ materially from historical results as well as from the results expressed in, anticipated or implied by these forward-looking
statements. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
Readers are also urged to carefully review and consider
the various disclosures made by us in this Report and in our other reports we file with the Securities and Exchange Commission, including
our periodic reports on Forms 10-Q and current reports on Form 8-K.
All references in this Annual Report on Form 10-K
to “LFER,” “Life On Earth, Inc. the “Company,” “we,” “us” or “our” mean
Life On Earth, Inc.
PART I
ITEM 1. BUSINESS
COMPANY OVERVIEW
Life On Earth, Inc. is a holding company operating
through wholly owned subsidiaries. We were previously a brand accelerator and incubator company that was focused on building and scaling
concepts in the natural consumer products category (“CPG”). During the fiscal year ended May 31, 2021, we discontinued our
wholesale beverage distribution operations, and announced our intention to divest away from the previous business as a CPG company. Accordingly,
the Company’s results of operations for the year ended May 31, 2021, reflected a charge in the aggregate amount of $25,135 for the
discontinued operations. In May 2021, we acquired a wholly owned subsidiary, Smart Axiom, Inc. which we then divested effective December
31, 2021 (See, SmartAxiom). Effective January 1, 2022, we acquired conditional ownership of four subsidiary operations which included
CareClix, Inc., a Virginia corporation, CareClix Services, Inc., a Florida corporation, MyCareClix, Inc., a Florida corporation, and CareClix
RPM, Inc., a Florida corporation (collectively, the “CareClix Group”), in an Initial Closing, subject to several conditions,
with a May 31, 2022 drop dead automatic rescission if certain conditions were not met. Effective May 31, 2022, those conditions were not
met, the agreed consideration was not paid, and the CareClix Group has been removed as of May 31, 2022. (See, CareClix Group).
SmartAxiom
In May
2021, we acquired SmartAxiom, Inc. (“SA”) from its former shareholders in exchange for consideration consisting of 13,000,000
shares of our common stock; 210,000 shares of a new Series D Convertible Preferred stock, convertible,
over an eighteen month earn out schedule, into our common stock with a floor price of twenty cents. On March 8, 2022, we executed a Stock
Purchase and Mutual Release Agreement (the “Agreement”) under which we divested our ownership of SA, effective December 31,
2021. Under the Agreement, we agreed to transfer all ownership in SA to Amit Biyani, the CEO of SA, in exchange for Mr. Biyani’s
agreement to return for cancellation: (ii) 7,974,695 shares of common stock; and (ii) 128,822
shares of Series D Preferred Stock. In addition, SA and Mr. Biyani agreed to arrange for the return and cancellation of the remaining
outstanding 64,942 shares of Series D Preferred Stock currently held by other former shareholders of SA. By agreement among the parties,
the divestiture of SA was deemed legally effective as of December 31, 2021. The Agreement also contained mutual releases amongst the parties.
1
In connection with the Agreement, SA issued to the
Company an 8% Unsecured Convertible Note in the amount of $250,000 dated December 31, 2021 (the “Note”). The Note bears interest
at a rate of 8 percent per year, with all principal and interest due on or before February 28, 2024. All unpaid principal and interest
owing under the Note may, at our option, may be converted, in whole, into a number of fully paid and non-assessable shares of common stock
of SA having a value equal to the Note balance, converted at an assumed total valuation of SA of $6,250,000 on a fully diluted basis.
At May 31, 2022, the Company has determined that collection on the Note is doubtful and accordingly, has established an allowance for
doubtful accounts in the amount of $250,000 by recording a charge to discontinued operation for the year ended May 31, 2022.
During Fiscal 2022, through December 31, 2021, SA
incurred a net loss of $971,091, which has been recorded as a part of the loss on discontinued operations for the year ended May 31, 2022.
The following table summarizes the loss
on disposition of the SA subsidiary:
Net assets sold |
|
$ |
1,669,584 |
|
Sales Price |
|
$ |
534,305 |
|
Loss from sale of Subsidiary |
|
$ |
1,135,279 |
|
The CareClix Group
On December 17, 2021, we entered into
a Stock Purchase Agreement (“SPA”) with CareClix Holdings, Inc., a Florida corporation (“SOLI”) to acquire four
operating subsidiaries of SOLI. On December 31, 2021, under the terms of a Management Operating Agreement, we agreed to a conditional
partial closing of the transaction set forth in the SPA (the “Interim Closing”) with the final closing conditioned on the
effectiveness of a registration statement to be filed by us with the SEC for the common shares to be issued by us as the consideration
for the acquisition. The Management Operating Agreement provided that i the registration statement was not filed by us and declared effective
by May 31, 2022, the Interim Closing would be rescinded, and the CareClix Group would not be part of the Company.
In the partial closing, we acquired 100% conditional
ownership of the operating subsidiaries of SOLI, which included CareClix, Inc., a Virginia corporation, CareClix Services, Inc., a Florida
corporation, MyCareClix, Inc., a Florida corporation, and CareClix RPM, Inc., a Florida corporation (collectively, the “CareClix
Group”). In exchange for ownership of the CareClix Group at the Interim Closing, we agreed to issue the following securities to
the common shareholders of SOLI:
|
1. |
260,000,000 shares of our common stock*. |
|
2. |
4,000,000 shares of our Series A Preferred Stock to Mr. Charles Scott, the Chairman and majority shareholder of SOLI, with 2,500,000 shares issued at the December 31, 2021 partial closing, 600,000 shares to be issued 45 days after closing, and 900,000 shares to be issued 90 days after closing. All of these shares have been issued. |
* In the original SPA, we
agreed to issue 50,000,000 shares of our common stock plus 2,100,000 shares of a new class of preferred stock to be designated as Series
E Preferred Stock. The shares of Series E Preferred stock would have a convertibility ratio of 100 to 1 into our shares of common stock
with conversion occurring automatically when our Articles of Incorporation had been amended to authorize sufficient common shares for
the conversion. Subsequently, our Articles of Incorporation have been amended so the need for the
Series E Convertible Preferred has been eliminated, and a total of 260 million common shares will be issued to the former Solei common
shareholders. The net effect of this issuance will be that common shares of SOLI held before the transaction will be exchanged
for our common shares on a 1 for 1 basis.
We also agreed to undertake an audit of the
financial statements of the CareClix Group for the registration statement, to appoint three new directors and, by a side agreement with
our former directors, Fernando Leonzo, John C. Romagosa, Mahmood Khan and Robert Gunther (collectively the “Former Management”),
to transfer the Series A Preferred shares held by them, with 600,000 shares cancelled and reissued to Charles Scott within 45 days and
the remaining 600,000 shares cancelled and reissued to Mr. Scott when the remaining holders were no longer directors but in no less than
one year. Each of the four members of Former Management also granted an irrevocable proxy to vote the Series A Preferred stock held by
each of them to Mr. Scott. Since the Series A Preferred stock carries voting rights equal to 50 (later amended to 60) votes per share,
voting with the common stock, voting control rests with the Series A Preferred, and the stated intent of the proposed acquisition was
that Charles Scott, principal shareholder of the CareClix Group, would acquire voting control of us, with 5,200,000 shares of Series A
Preferred stock. The proxies were irrevocable unless the CareClix Group audit was not completed within 75 days after closing of the acquisition,
which has not occurred.
2
The Interim Closing was designed to allow
the CareClix Group to be treated as our operating subsidiaries pending the Final Closing, which was subject to the effectiveness of a
registration statement on Form S-4 to be filed registering the issuance of our shares of common stock to the common shareholders of CareClix,
as the consideration for the acquisition of the CareClix Group. The initial 2,500,000 shares of Series A Preferred stock were issued as
agreed to Charles Scott by Former Management; however in March and April 2022, differences arose between the CareClix Group principals
and Former Management, resulting in several defaults under the Management Operating Agreement by
us, as disclosed in the Quarterly Report on Form 10-Q for the quarter ended February 28, 2022, filed for the Company by Former Management.
With the transaction drop dead date of May 31, 2022 approaching and no work on the required
audit of the CareClix Group or the required S-4 registration statement yet initiated by Former
Management, Charles Schott, as controlling shareholder and our director, proposed on several occasions in April 2022 to Former Management,
who were then four out of six of our directors and all of our corporate officers, that either the CareClix Croup transaction should be
rescinded or at least two but preferably four of the Former Management resign to allow Mr. Scott and his management team to assume full
operating control of the Company, by assuming all officer positions. Our Former Management initially agreed to resign but then advised
Mr. Scott that they intended to remain as a majority of the Board of Directors and as the
only corporate officers. On April 26, 2022, Mr. Scott as a director and majority voting shareholder, voted to remove Fernando Leonzo and
John Romagosa as directors and officers under Delaware law, and on April 29, 2022, voted to remove Robert Gunther and Mahmood Khan as
our officers and directors.
As previously reported, on May 2, 2022,
acting as our remaining directors, Mr. Scott and Dr. Korangy elected new corporate officers, caused the reported defaults in the Management
Operating Agreement to be cured, and extended the May 31, 2022 drop dead date for the CareClix Group acquisition by approving and executing
an Amended Management Operating Agreement. Thereafter, as our new management, they retained
our independent auditor to audit our financial results for the fiscal year ended May 31, 2022, retained the same independent audit firm
to audit the CareClix Group for the two fiscal years ended May 31, 2020 and 2021, a requirement
of the Management Operating Agreement and the required S-4 registration statement to complete the Final Closing. The CareClix Group also
advanced more than $120,000 in funds to the Company or for the Company to pay ongoing and accrued expenses which we are unable to pay
for lack of funds.
The required audits were completed and the
Annual Report for the fiscal year ended May 31, 2022 was completed and ready to file when Mr. Scott received an email copy of a purported
“derivative action” filed by the Former Management seeking to reinstate themselves as our officers and directors and seeking
to rescind the CareClix Group acquisition by rescinding the Amended Management Operating Agreement. Mr. Scott immediately responded that
he was agreeable to this, as he had previously offered in April 2022, and, on September 15, 2022, our Board of Directors voted to rescind
the Amended Management Operating Agreement retroactively. As a result, the Interim Closing drop dead date of May 31, 2022 resulted in
the termination of the CareClix Group acquisition for failure of consideration, and the CareClix Group accordingly is not a part of the
Company as of May 31, 2022. Therefore, the financial results of our operations contained in this Annual Report include only the results
of Life on Earth, Inc. for the fiscal year ended May 31, 2022.
Other Discontinued Operations
During the fiscal year, our Board of
Directors also resolved to dispose of our remaining non-operating subsidiaries Victoria’s Kitchen and The Chill Group
for a net loss of $261,110.
3
Our principal executive offices currently are virtual
offices located at 1270 N. Wickham Road, Suite 13A, No. 1019, Melbourne, FL 32935 and our telephone number (833) 516-0606.
Coronavirus Risks
In December 2019, a novel strain of coronavirus
was reported to have surfaced in Wuhan, China, which has and is continuing to spread throughout China and other parts of the world, including
the United States. On January 30, 2020, the World Health Organization declared the outbreak of the coronavirus disease (COVID-19) a “Public
Health Emergency of International Concern.” On January 31, 2020, U.S. Health and Human Services Secretary Alex M. Azar II declared
a public health emergency for the United States to aid the U.S. healthcare community in responding to COVID-19, and on March 11, 2020
the World Health Organization characterized the outbreak as a “pandemic”.
The ultimate extent of the impact of any
epidemic, pandemic or other health crisis on our business, financial condition and results of operations will depend on future developments,
which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of such epidemic,
pandemic or other health crisis and actions taken to contain or prevent their further spread, among others. The significant outbreak of
COVID-19 has resulted in a widespread health crisis that has adversely affected the economies and financial markets worldwide, and may
continue to do so, which could adversely affect our business, results of operations and financial condition.
Employees
We currently have no direct employees and act solely
as a public holding company.
Going Concern Qualification
Several conditions and events may cast substantial
doubt about our ability to continue as a going concern. We have incurred net losses from inception of more than $23,000,000, have no cash
or other assets and will require additional financing in order to continue any business activities.
Intellectual Property Protection
We have secured a registered trademark for our name
and logo. We also hold trademarks registered for the Victoria’s Kitchen and Just Chill brands.
4
ITEM 1A. RISK FACTORS
As a “Smaller Reporting Company”, we are
not required to provide this information.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None
ITEM 2. PROPERTIES
We currently maintain our principal office in Melbourne,
Florida
We maintain a website at http://www.lifeonearthinc.com/
and the information contained on that website is not deemed to be a part of this annual report.
ITEM 3. LEGAL PROCEEDINGS
Complaint by Note Holder
On December 14, 2020, we received a Complaint from
a note holder, L & H, Inc. (“L&H”), filed in the First Judicial District Court of Nevada, Carson City, alleging breaches
of contract regarding our failure to repay amounts due or failing to issuing shares upon demand and breach of Implied covenant of good
faith and fair dealing in connection with the $110,000 September 10, 2019 Convertible Promissory Note between L&H and the Company.
On May 26, 2022, the Court entered judgment against us in the total amount of $171,116, including the principal sum, accrued interest,
default interest of $44,428. Attorney’s fees of $10,000 and $1,127 in costs, which has been recorded as a current liability in our
condensed consolidated balance sheet for the year ended May 31, 2022.
See, Item 9B. Other Information regarding a “derivative
action” filed by our Former Management.
ITEM 4. MINE SAFETY DISCLOSURE
Not applicable.
PART II
ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
We have two classes of stock outstanding, Common Stock
and Preferred Stock, in designated classes as Series A, Series B, Series C and Series D Preferred. Our Common Stock is quoted on the OTC
Bulletin Board under the symbol “LFER”.
The following table sets forth the high and low reported
closing prices per share of our Common Stock for the period’s indicated. There is no established public trading market for our Series
A Preferred Stock, our Series B Preferred Stock, our Series C Preferred and our Series D Preferred Stock.
|
|
2022 |
|
|
2021 |
|
|
|
|
High |
|
|
|
Low |
|
|
|
High |
|
|
|
Low |
|
First quarter (June 1 to August 31, 2021) |
|
$ |
0.165 |
|
|
$ |
0.080 |
|
|
$ |
0.035 |
|
|
$ |
0.014 |
|
Second quarter (September 1 to November 30, 2021) |
|
$ |
0.135 |
|
|
$ |
0.058 |
|
|
$ |
0.083 |
|
|
$ |
0.021 |
|
Third quarter (December 1, 2021,to February 28, 2022) |
|
$ |
0.120 |
|
|
$ |
0.061 |
|
|
$ |
0.125 |
|
|
$ |
0.026 |
|
Fourth quarter (March 1 to May 31, 2022) |
|
$ |
0.068 |
|
|
$ |
0.016 |
|
|
$ |
0.211 |
|
|
$ |
0.070 |
|
The Company has not declared dividends and does not
intend to in the foreseeable future. The amount and frequency of future dividends will be determined by the Company’s Board of Directors
in light of the earnings and financial condition of the Company at such time, and no assurance can be given that dividends will be declared
or paid in the future.
5
Holders
As of September 23,
2022, there were 71,822,753 shares of Common Stock issued
and held by approximately 1,000 shareholders of record. As of September 23, 2022, there were 5,200,000 shares of Series A Preferred
Stock issued and outstanding held by one shareholder of record. As September 23, 2022, there were 100,000 Series B Preferred Share issued
and outstanding held by 3 holders; As of September 23, 2022, there were 2,613,375 Series C Preferred Shares issued to 10 Shareholders;
and there were 18,236 Series D Preferred Shares issued and outstanding to 3 shareholders.
During the year ended May 31, 2022, and May 31, 2021,
the Company issued 2,581,592 and 368,593 common shares, respectively, in exchange for financing and services provided by select individuals
and or vendors. The shares were issued at prices ranging from $0.07 to $0.156 per share.
Also, on February 4, 2022, we issued shares of common
stock and Series C preferred shares to our Former Management at par value in exchange for services provided. The following table summarizes
the shares issued to the Former Management. The difference between the fair value of the shares acquired and the acquisition price has
been recognized as officers’ compensation in the statement of operations for the year ended May 31, 2022:
|
|
Number of Shares Acquired |
|
Acquisition Price |
|
Common Stock |
|
Compensation |
|
Common Stock |
|
|
|
|
Common
Stock |
|
Series C
Preferred |
|
Consideration
Shares |
|
Common
Stock |
|
Series C
Preferred |
|
Consideration
Shares |
|
Common
Stock |
|
Series C
Preferred |
|
Consideration
Shares |
|
Total |
Robert Gunther |
|
|
2,678,672 |
|
|
|
327,393 |
|
|
|
654,786 |
|
|
$ |
2,678 |
|
|
$ |
327 |
|
|
$ |
— |
|
|
$ |
204,115 |
|
|
$ |
327,066 |
|
|
$ |
50,549 |
|
|
$ |
581,731 |
|
John Romagossa |
|
|
2,815,279 |
|
|
|
344,090 |
|
|
|
688,180 |
|
|
$ |
2,815 |
|
|
$ |
344 |
|
|
$ |
— |
|
|
$ |
214,525 |
|
|
$ |
343,746 |
|
|
$ |
53,127 |
|
|
$ |
611,398 |
|
Fernando Leonzo |
|
|
3,019,602 |
|
|
|
369,062 |
|
|
|
738,124 |
|
|
$ |
3,020 |
|
|
$ |
369 |
|
|
$ |
— |
|
|
$ |
230,093 |
|
|
$ |
368,693 |
|
|
$ |
56,983 |
|
|
$ |
655,769 |
|
Mahmood Kahn |
|
|
3,989,624 |
|
|
|
487,621 |
|
|
|
975,242 |
|
|
$ |
3,990 |
|
|
$ |
486 |
|
|
$ |
— |
|
|
$ |
304,009 |
|
|
$ |
487,135 |
|
|
$ |
75,289 |
|
|
$ |
866,433 |
|
|
|
|
12,503,177 |
|
|
|
1,528,166 |
|
|
|
3,056,332 |
|
|
$ |
12,503 |
|
|
$ |
1,526 |
|
|
$ |
— |
|
|
$ |
952,742 |
|
|
$ |
1,526,640 |
|
|
$ |
235,949 |
|
|
$ |
2,715,331 |
|
A portion of the total compensation was allocated
to payment of accrued officer compensation for prior years reflected on the books, and the balance was charged to current compensation.
6
Dividends
We have never declared any cash dividends with respect
to our Common Stock. Future payment of dividends is within the discretion of the Board of Directors and will depend on earnings, capital
requirements, financial condition and other relevant factors. Although there are no material restrictions limiting or that are likely
to limit, our ability to pay dividends on our Common Stock, we presently intend to retain future earnings, if any, for use in our business.
We have no present intention to pay cash dividends on our Common Stock.
Recent Sales
or Issuances of Unregistered Securities
During the fiscal year ended May 31, 2022, we issued
the following equity:
Preferred Stock
A total of 4 million shares of Series A Preferred
Stock were issued to Charles O. Scott as part of the acquisition of the CareClix Group of companies. The other outstanding Series A Preferred
shares were cancelled and reissued to Mr. Scott as part of the acquisition of the CareClix Group of companies. Mr. Scott currently holds
all 5,200,000 of the issued and outstanding Series A Preferred stock.
A total of 2,393,375 Series C Preferred shares were
issued in the year ended May 31, 2022, all of which were issued at $1.00 per shares except for the shares issued to Former Management,
which were issued at $0.001 per share. On January 14, 2022, 50,000 Series C Preferred shares were converted into 525,000 common shares.
During June 2022, 20,000 Series C Preferred shares were cancelled.
Additional shares of common stock, referred to as
“Consideration Shares” were issued to Former Management based on the initial Series C shares issued to them.
Common Stock:
The following shares of common stock were issued during
the fiscal year ended May 31, 2022:
# of Shares |
|
Reason |
|
572,727 |
|
|
Chill Grp Contingency shares |
|
5,822,063 |
|
|
Consideration shares |
|
1,431,012 |
|
|
Services |
|
15,784,793 |
|
|
Debt Settlement |
|
650,000 |
|
|
Legal Settlement |
|
525,000 |
|
|
Preferred C Conversion |
|
13,000,000 |
|
|
SA Acquisition |
|
12,503,177 |
|
|
Stock Purchase |
|
50,288,772 |
|
|
Total |
Included in the above, the following shares were issued
to related parties during the year ended May 31, 2022:
# of Shares |
|
Holder |
|
3,757,726 |
|
|
Fernando Leonzo |
|
4,391,571 |
|
|
John Romagosa |
|
152,500 |
|
|
Juan Romagosa** |
|
5,486,866 |
|
|
Mahmood Khan |
|
183,000 |
|
|
Pirjo J. Polario Khan* |
|
3,333,458 |
|
|
Robert Gunther |
|
17,305,121 |
|
|
Total |
* Pirjo J. Polario Khan is the spouse of Mahmood Khan
** Juan Romagosa is the father of John Romagosa
During the year ended May 31, 2022, 8,014,695 shares
common stock were cancelled, of which, 7,974,695 shares of common stock were cancelled as a result of the SA Stock Purchase and Mutual
Release Agreement.
There were 29,548,676 shares of our common stock issued
and outstanding at May 31, 2021 and 71,822,753 shares issued at May 31, 2022 and at the date of this report.
7
ITEM 6. SELECTED FINANCIAL DATA
Not applicable.
ITEM 7. MANAGEMENT’S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion of our financial condition
and results of operations contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives,
expectations and intentions. As described at the beginning of this Annual Report on Form 10-K, our actual results could differ materially
from those anticipated in these forward-looking statements. Factors that could contribute to such differences include those discussed
at the beginning of this Report, below in this section and in the section above entitled “Risk Factors.” You should not place
undue reliance on these forward-looking statements, which apply only as of the date of this Report. Except as required by law, we undertake
no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date of this Report,
or to reflect the occurrence of unanticipated events. You should read the following discussion and analysis in conjunction with our consolidated
financial statements and the accompanying notes thereto included elsewhere in this Report.
CURRENT OPERATIONS
With the termination of the CareClix Companies’
acquisition at May 31, 2022, we have no current operations at May 31, 2022.
8
CRITICAL ACCOUNTING
POLICIES AND ESTIMATES
The preparation of financial statements and related
disclosures in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires
management to make judgments, assumptions and estimates that affect the amounts reported in our financial statements and accompanying
notes. The condensed financial statements included in this Report include the financial results of Life on Earth, Inc. for the full fiscal
year ended May 31, 2022. The discussion and analysis of our financial condition and results of operations is based upon our consolidated
financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation
of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical
experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis
for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results
may differ from these estimates under different assumptions or conditions, or if management made different judgments or utilized different
estimates. Many of our estimates or judgments are based on anticipated future events or performance, and as such are forward-looking in
nature, and are subject to many risks and uncertainties, including those discussed below and elsewhere in this Report. We do not undertake
any obligation to update or revise this discussion to reflect any future events or circumstances. There are certain critical accounting
estimates that we believe require significant judgment in the preparation of our consolidated financial statements. We have identified
below our accounting policies that we use in arriving at key estimates that we consider critical to our business operations and the understanding
of our results of operations. This is not a complete list of all of our accounting policies, and there may be other accounting policies
that are significant to us. For a detailed discussion on the application of these and our other accounting policies, see Note 1 to Consolidated
Financial Statements of this Report.
Revenue Recognition
We recognize revenue under ASU No. 2014-09,
“Revenue from Contracts with Customers (Topic 606),” (“ASC 606”). The core principle of the revenue standard is
that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the
consideration to which the company expects to be entitled in exchange for those goods or services. We only apply the five-step model (as
described in Note 1 to the Consolidated Financial Statements of this Report) to contracts when it is probable that we will collect the
consideration it is entitled to in exchange for the goods and services transferred to the customer.
We recognize when the promised goods or services are
transferred to the customer. The amount of revenue recognized should equal the total consideration expected to be received in return for
the goods or services. ASC 606 creates a five-step approach that should be applied when determining the amount and timing of revenue recognition:
• Step 1: Identify the contract with a customer
• Step 2: Identify the performance obligations
in the contract
• Step 3: Determine the transaction price
• Step 4: Allocate the transaction price to
the performance obligations in the contract
• Step 5: Recognize revenue when (or as) the
entity satisfies a performance obligation
9
Goodwill and Intangible
Assets
Goodwill represents
the excess of the purchase price of acquired businesses over the estimated fair value of the identifiable net assets acquired. Goodwill
and other intangibles are reviewed for impairment annually or more frequently when events or circumstances indicates that the carrying
value of a reporting unit more likely than not exceeds its fair value. The goodwill impairment test is applied by performing a qualitative
assessment before calculating the fair value of the asset. If, on the basis of qualitative factors, it is considered more likely than
not that the fair value of the asset is greater than the carrying amount, further testing of goodwill for impairment is not required.
If the carrying amount of the asset exceeds the asset’s fair value, an impairment loss is recognized in an amount equal to that
excess, limited to the total amount of goodwill allocated to that asset. Identifiable intangible assets acquired in business combinations
are recorded at the estimated acquisition date fair value. Finite lived intangible assets are amortized over the shorter of the contractual
life or their estimated useful life using the straight-line method, which is determined by identifying the period over which the cash
flows from the asset are expected to be generated.
Off-Balance Sheet
Arrangements
We have no significant off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.
Inflation
The amounts presented in the financial statements
do not provide for the effect of inflation on our operations or financial position. The net operating losses shown would be greater than
reported if the effects of inflation were reflected either by charging operations with amounts that represent replacement costs or by
using other inflation adjustments.
10
LIQUIDITY AND CAPITAL
RESOURCES
Several conditions and events may cast substantial
doubt about our ability to continue as a going concern. We have incurred net losses from inception of more than $23,000,000, have no cash
or operating assets and require additional financing on an ongoing basis to engage in business. We had negative working capital of more
than $1,700,000 as of May 31, 2022.
For the fiscal year ended May 31, 2022, our consolidated
loss from operations was $1,988,237, which included officers’ compensation expense of $1,545,526 to our Former Management.
Our future capital requirements will depend on
numerous factors including, but not limited to, continued progress in finding business opportunities. We have experienced recurring losses
from operations and negative cash flows from operating activities to date, but all of the unsuccessful prior operations have now been
closed. This situation creates uncertainties about our ability to execute our business plan, finance operations, and indicated substantial
doubt in the past about our ability to continue as a going concern.
CASH FLOW
Our primary sources of liquidity have been cash from
sales of common and preferred shares, the issuance of convertible promissory notes and from lines of credit. And the advance of more than
$120,000 from the CareClix Companies, represented by a promissory note.
WORKING CAPITAL
As of May 31, 2022, the Company had total current
assets of $0 as compared to $113,656 as of May 31, 2021, and total current liabilities of $1,703,942 as compared to $9,881,134 as of May
31, 2021. As of May 31, 2022, we had negative working capital of $1,703,942 as compared to $9,767,478 as of May 31, 2021. The decrease
in negative working capital during the year ended May 31, 2022, related, primarily to the decrease in the accrued cost of the acquisition
of Smart Axiom of approximately $5,044,127. In addition, there was a decrease in current assets in 2022 compared to 2021 of $113,656.
RESULTS OF OPERATIONS
FOR THE YEARS ENDED MAY 31, 2022 and 2021
Revenues
The Company recorded sales from continuing
operations for the year ended May 31, 2022 of approximately $0 as compared to $0 during 2021.
Cost of Goods Sold and Gross Profit
Gross profit during the year ended May 31, 2022, was
approximately $0 as compared to $0 for the year ended May 31, 2021.
11
Operating Expenses
Operating expenses from continuing operations were
approximately $1,948,000 for the year ended May 31, 2022 as compared to $664,000 for the year ended May 31, 2021. The increase in operating
expenses of approximately $1,285,000 resulted primarily from an increase in officers’ compensation of $1,361,000 and increased professional
fees of $60,000.
Other Expense
During the year ended May 31, 2022, the Company recorded
interest and finance costs from continuing operations of $502,832, as compared to $423,546 during the year ended May 31, 2021. The interest
and finance costs incurred by the Company reflect the cost of the debt incurred by the Company to finance operations. During the year
ended May 31, 2022, the Company recorded a credit for the change in the fair value of contingent consideration of $352,227 as compared
to a charge for the change in the fair value of contingent consideration by $357,955 during the year ended May 31, 2021, related to the
acquisition of JCG, which arose from the measurement of LFER stock on the 12-month anniversary of the acquisition and subsequent Balance
Sheet reporting dates. During the year ended May 31, 2022, the Company recorded a credit change in the fair value of derivative liability
of $110,588 as compared to $36,127 during the year ended May 31, 2021.
Net Loss
The Company recorded a net loss for the year ended
May 31, 2022, of $4,605,717 which was an increase from a net loss of $1,434,073 for the year ended May 31, 2021. In addition to the above
factors, during the year ended May 31, 2022, the Company recorded a loss on discontinued operations of $1,221,091 during 2022 as compared
to $25,135 during 2021, and, during the year ended May 31, 2022, the Company recorded a loss on the sale of a subsidiary of $1,135,279,
related to the sales of SA and a loss on the disposal of subsidiaries of $261,110 related to the disposal of VK and JCG.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET
RISK
As a “Smaller Reporting Company”, the
Company is not required to provide this information.
ITEM 8. FINANCIAL STATEMENTS
The audited financial statements are included beginning
immediately following the signature page to this report. See Item 15 for a list of the financial statements included herein.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH
ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None
12
ITEM 9A. CONTROLS
AND PROCEDURES
We maintain a system of disclosure controls
and procedures that are designed to ensure that information required to be disclosed by is in the reports we file or submit under the
Act is recorded, processed, summarized, and reported within the time periods specified in the Commission’s rules and forms, and
to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Principal
Accounting Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
Our management, including our Chief Executive
Officer and Principal Accounting Officer, or persons performing similar functions, as appropriate does not expect that our disclosure
controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) (“Disclosure Controls”) will prevent
all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource
constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company
have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns
can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion
of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain
assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated
goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due
to error or fraud may occur and not be detected. We monitor our Disclosure Controls and make modifications as necessary; our intent in
this regard is that the Disclosure Controls will be modified as systems change, and conditions warrant.
As of May 31, 2022, we carried out an evaluation,
under the supervision and with the participation of our principal executive officer and our principal accounting officer or persons performing
similar functions, as appropriate, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on
this evaluation, we have concluded that our disclosure controls and procedures were not effective as of the end of the period covered
by this report.
The determination that our disclosure controls
and procedures were not effective as of May 31, 2022 is a result of inadequate staffing and supervision within our Company and failure
to adhere to corporate governance policy and applicable corporate law. The Company plans to expand its accounting and operations staff
as the business of the Company expands, to appoint Audit and Corporate Governance Committees of our Board made up of independent Board
members, and to review all corporate governance policies.
MANAGEMENT’S REPORT ON INTERNAL CONTROLS
OVER FINANCIAL REPORTING
CHANGES IN INTERNAL CONTROLS OVER FINANCIAL REPORTING
There have been no changes
in our internal controls over financial reporting during the year1 ended May 31, 2022, that
have materially affected or are reasonably likely to materially affect our internal controls.
13
ITEM 9B. OTHER INFORMATION
Change in Management
As part of the proposed acquisition of the CareClix
Companies, including the letter of intent in November 2021, the Stock Purchase Agreement of December 17, 2021, the Management Operating
Agreement of December 31, 2021 and thereafter through March 2022, the principal officers and management of the CareClix Companies and
our former management, discussed and agreed that following the acquisition, the CareClix Companies would continue to be managed and operated
by the CareClix management team but with the additional assistance and advice of our former management; and that we would be managed and
controlled by a new combined management team of seven directors, initially including our four Former Managements and three new directors
nominated by the CareClix Companies, The acquisition agreements expressly provided for this structures, as well as the change of control
of Life on Earth, Inc. by the issuance of 260 million common shares to the former CareClix Holdings shareholders, with transition voting
control transferred at the December 31, 2021 Interim Closing by the issuance of 4,000,000 Series A Preferred stock to Charles Scott and
the transfer of the then outstanding Series A Preferred stock held by the four former directors, to Mr. Scott. It was also represented
that two of the four former directors would be resigning to pursue other matters within 45 days but would remain available on a consulting
basis to assist with the transition and to support the growth of the new virtual health operations. Resignations of these two directors
and officers was not an express condition of the Interim Closing but surrender of the Series A Preferred stock held by them in that time
period was an express condition.
Unknown to the CareClix Companies management, our
four former directors voted on December 30, 2021, as the then four sole members of our Board of Directors, to issue our common shares
to themselves in payment and discharge of accrued compensation of more than $2,500,000, and authorized the issue of 12,503,177 common
shares and 1,528,166 Series C Preferred shares, both at par value, $0.001 per shares, with an additional 3,0586,332 common shares issued
as “consideration shares” for the preferred, issued for no consideration.. This action resulted in the total issued shares
of common stock to increase by 15,559,509 shares, an increase of approximately 33%. This action was not disclosed to CareClix Companies
management before the Interim Closing of the acquisition on December 31, 2022 for the common shares was $0.10 per share and the Series
C Preferred shares were being offered and sold to the public concurrently at $1.00 per share
Although the Form 8-K makes reference to an “agreement”
“effective February 4, 2022”, to undertake this stock issue, the only documentation is a copy of minutes of a Board of Directors
meeting approving the issuance on December 30, 2021. This stock issue and resulting compensation was reported in the Form 10-Q report
for the quarter ended February 28, 2022, signed by or on behalf of the former directors as follows:.
Accounting for Equity Awards
The cost of services received in exchange for an award
of equity instruments related to employees and non-employees is based on the grant-date unadjusted fair value of the award and allocated
over the requisite service period of the award.
Shares of common stock issued for services
The Company issues shares of common stock in exchange
for financing and services provided by select individuals and or vendors. During the year ended May 31, 2022, and 2021 the Company issued
2,581,592 and 0 shares, respectively. The shares were issued at prices ranging from $0.07 to $0.156 per share.
Also, on February 4, 2022, the Company issued shares
of common stock and Series C preferred shares to members of the Board of Directors at par value in exchange for services provided. The
following table summarizes the shares issued to the members of the Board of Directors. The difference between the fair value of the shares
acquired and the acquisition price has been recognized as officers’ compensation in the statement of operations for the year ended
May 31, 2022:
|
|
Number of Shares Acquired |
|
Acquisition Price |
|
Common Stock |
|
Compensation |
|
Common Stock |
|
|
|
|
Common
Stock |
|
Series C
Preferred |
|
Consideration
Shares |
|
Common
Stock |
|
Series C
Preferred |
|
Consideration
Shares |
|
Common
Stock |
|
Series C
Preferred |
|
Consideration
Shares |
|
Total |
Robert Gunther |
|
|
2,678,672 |
|
|
|
327,393 |
|
|
|
654,786 |
|
|
$ |
2,678 |
|
|
$ |
327 |
|
|
$ |
— |
|
|
$ |
204,115 |
|
|
$ |
327,066 |
|
|
$ |
50,549 |
|
|
$ |
581,731 |
|
John Romagossa |
|
|
2,815,279 |
|
|
|
344,090 |
|
|
|
688,180 |
|
|
$ |
2,815 |
|
|
$ |
344 |
|
|
$ |
— |
|
|
$ |
214,525 |
|
|
$ |
343,746 |
|
|
$ |
53,127 |
|
|
$ |
611,398 |
|
Fernando Leonzo |
|
|
3,019,602 |
|
|
|
369,062 |
|
|
|
738,124 |
|
|
$ |
3,020 |
|
|
$ |
369 |
|
|
$ |
— |
|
|
$ |
230,093 |
|
|
$ |
368,693 |
|
|
$ |
56,983 |
|
|
$ |
655,769 |
|
Mahmood Kahn |
|
|
3,989,624 |
|
|
|
487,621 |
|
|
|
975,242 |
|
|
$ |
3,990 |
|
|
$ |
486 |
|
|
$ |
— |
|
|
$ |
304,009 |
|
|
$ |
487,135 |
|
|
$ |
75,289 |
|
|
$ |
866,433 |
|
|
|
|
12,503,177 |
|
|
|
1,528,166 |
|
|
|
3,056,332 |
|
|
$ |
12,503 |
|
|
$ |
1,526 |
|
|
$ |
— |
|
|
$ |
952,742 |
|
|
$ |
1,526,640 |
|
|
$ |
235,949 |
|
|
$ |
2,715,331 |
|
14
As noted, the shares were issued in payment of accrued
salaries and compensation of $2,061,676, with the excess of the fair value of the shares over the issuance price recorded as additional
current compensation. At the time the shares were issued in February 2022, the closing market price of our common shares was $0.077 and
the shares of Series A Preferred stock were then offered and sold at $1.00 per share, plus 10 common shares as “consideration shares”
and an annual dividend of $0.10 per share.
In addition to issuance of common and Series C Preferred
shares to themselves at par value, the four former directors refused to issue the Series A Preferred as agreed to transfer control of
the Company, refused and failed to resign as directors as agreed, and otherwise defaulted on the terms of the CareClix Companies’
acquisition. Following multiple discussions, of these and other actions concerning to new management, the four former directors agreed
to resign as officers and directors, but only if certain new conditions were first agreed to and completed by the Company.
In late April 2022, the four former directors and
officers all were terminated by action of the remaining Board of Directors and majority vote of the shareholders, as provided by Delaware
law. Following their termination, the four individuals then failed and refused to turn over corporate records, files and access to vendors
and creditors, resulting in our inability to complete a timely audit of our financial records for the year ended May 31, 2022.
15
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND
CORPORATE GOVERNANCE
Executive Officers and Directors
Below are the names and certain information regarding
our current and former executive officers and directors during fiscal year ended May 31, 2022:
Name |
Age |
Title |
|
Date first appointed |
Date of Termination |
Fernando Leonzo |
|
50 |
|
Former Chairman and Director |
|
April 15, 2013 (inception) |
April 26, 2022 |
|
|
|
|
|
|
|
|
Robert Gunther |
|
72 |
|
Former Chief Operations Officer, Treasurer, Secretary and Director |
|
April 15, 2013 (inception) |
April 29, 2022 |
|
|
|
|
|
|
|
|
John Romagosa |
|
42 |
|
Former President and Director |
|
October 10, 2014 |
April 26, 2022 |
|
|
|
|
|
|
|
|
Mahmood Khan |
|
70 |
|
Former CEO and Director |
|
July 1, 2021 |
April 29, 2022 |
|
|
|
|
|
|
|
|
Charles O. Scott |
|
68 |
|
Chairman and CEO |
|
January 1, 2022 as Director |
Current |
|
|
|
|
|
|
|
|
S. John Korangy, MD |
|
50 |
|
President and Director |
|
January 1. 2022 as Director |
Current |
Directors are elected to serve until the next annual
meeting of stockholders, unless removed, and until their successors are elected and qualified. Biographical information of each current
officer and director is set forth below.
Fernando Leonzo, was our Chairman
of the Board of Directors since April, 2014, and was a founder. He was terminated as an officer and director in April 2022.
Robert Gunther, the former Chief Operations
Officer, Treasurer and Director since April, 2014, was a founder of the Company since its inception in April of 2013. He was terminated
as an officer and director in April 2022.
John Romagosa, former President and Director
since October 2014. He was terminated as an officer and director in April 2022.
Mahmood Khan – former CEO, Director from
February, 2021 and Director from June, 2021. He was terminated as an officer and director in April 2022.
Charles O. Scott. Considered by many
to be a living legend in the life insurance sales industry, Scott grew from a one-man insurance agent into a multi-million-dollar start-up
incubator of insurance agents who have produced an estimated hundreds of millions of life insurance premium over a 40 plus year career.
His agency began working with Globe Life, Inc., in 1992 and, in his honor, the annual top Master General Agent Award at Globe Life is
named the “Charles O. Scott MGA” award. With his insurance firm established and well run by his loyal and experienced team,
Scott began to invest his time and money into the health and wellness industries. He has led many entrepreneurial efforts in the health
and wellness space as investor, director, or CEO. He is currently focused on the improvement virtual care can make in patient safety and
healthcare equity. Scott graduated University of Virginia where he studied sociology and economics and was a founding member of Phi Beta
Sigma Chapter. He lives with his family in Alexandria, VA. He currently serves on the board of directors of the Company.
16
S. John Korangy, MD, MPH, DABR is a board-certified,
fellowship-trained neuroradiologist and a pioneer in virtual care delivery. As a founder of CareClix he developed one of the most robust
virtual health platforms in the world with the goal of improving access to quality, cost effective health care services for patients.
Doctor Korangy received his medical degree and Masters in Public Health from George Washington University, then completed his residency
and his neuroradiology fellowship at Georgetown University Medical Center. Prior to founding CareClix, he served as Chief Medical Officer
and Department Chairman for United Radiology Services, a large radiology practice where he was able to successfully implement a teleradiology
program across multiple facilities and hospital while serving as Department Chairman of Good Samaritan Hospital as well. He has chaired
and served on numerous industry-advancing boards and committees in hospitals, medical groups, and medical societies.
Considered a pioneer in virtual health, he has helped
formulate standards and guidelines for the practice of telemedicine and has authored papers on telemedicine and the implementation of
virtual health on a global basis. Dr. Korangy speaks nationally about utilizing and deploying virtual health across the practice of medicine.
Lives with his family in Potomac, MD. He currently serves on the board of directors of the Company.
Jeffry Hollis, CPA. Controller and Secretary/Treasurer
has served as Managing Partner at Industrial Health – a group of physical therapy clinics serving the injured worker community around
Washington, D.C. and Richmond, Virginia. He also served as CEO of medical practices such as Blue Ridge Orthopedic & Spine Center for
over 20 years. Mr. Hollis attended the United States Military Academy at West Point before going on to earn a BBA in Marketing and an
MBA in Finance from James Madison University. He is best known for his charity work. Mr Hollis founded the Blue Ridge Orthopedic Foundation
and continues to serve as board member, advocate, leader and volunteer to a broad range of charities. He lives with his wife, and they
share time between Oaktown, Virginia and Ft Lauderdale, Florida.
Additional management functions are currently provided
by independent consultants, who are not directors or officers of the Company.
We have not yet established any committees of the
Board of Directors. The Company plans to form an Audit Committee, a Compensation Committee and a Governance Committee of the Board of
Directors, with appropriate charters, as soon as possible. The independent directors will also conduct an inquiry into the ethics and
potential misconduct of the former board members. We do not have a nominating committee or a nominating committee charter. Our two directors
perform all functions that would otherwise be performed by committees.
Additional management functions are currently provided
by independent consultants, who are not directors or officers of the Company.
Shareholder Communications
Currently, we do not have a policy with regard to
the consideration of any director candidates recommended by security holders. To date, no security holders have made any such recommendations.
Code of Ethics
We have adopted a written code of ethics (the “Code
of Ethics”) that applies to our principal executive officer, principal financial officer, principal accounting officer or controller,
and persons performing similar functions. We believe that the Code of Ethics is reasonably designed to deter wrongdoing and promote honest
and ethical conduct; provide full, fair, accurate, timely and understandable disclosure in public reports; comply with applicable laws;
ensure prompt internal reporting of code violations; and provide accountability for adherence to the code. To request a copy of the Code
of Ethics, please make written request to our Company at 1270 N. Wickham Road, Suite 13A-1019, Melbourne, FL 32935
Compliance with Section 16(a) of the Exchange Act
Our Common Stock is not registered pursuant
to Section 12 of the Exchange Act. On July 7, 2015, our common stock became registered pursuant to section 12g of the exchange act. Accordingly,
our officers, directors and principal shareholders are subject to the beneficial ownership reporting requirements of Section 16(a) of
the Exchange Act. Based solely on a review of the copies of these reports furnished to us from our directors and executive officers with
respect to our Fiscal Year 2022, we are aware that no required Section 16 reports were filed as required.
17
ITEM 11.
EXECUTIVE COMPENSATION
The following table sets forth information concerning
the total compensation paid or earned and accrued by each of our named executive officers (as defined under SEC rules) for the fiscal
year ended May 31, 2022, 2021 and 2020
Summary Compensation Table for Fiscal Years Ended
May 31, 2022, 2021 and 2020
Name/Position |
|
Year |
|
Salary |
|
Bonus |
|
Equity |
|
All |
|
Total |
|
|
|
|
|
|
|
|
Awards |
|
Other |
|
Compensation |
Fernando Leonzo1 |
|
|
2022 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
655,769 |
|
|
$ |
655,769 |
|
Former Chairman |
|
|
2021 |
|
|
$ |
30,000 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
30,000 |
|
|
|
|
2020 |
|
|
$ |
200,000 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
24,000 |
|
|
$ |
224,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert Gunther1 |
|
|
2022 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
581,731 |
|
|
$ |
581,731 |
|
Former Director, |
|
|
2021 |
|
|
$ |
30,000 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
30,000 |
|
COO, Sec/Treas |
|
|
2020 |
|
|
$ |
150,000 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
24,000 |
|
|
$ |
174,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
John Romagosa1 |
|
|
2022 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
611,398 |
|
|
$ |
611,398 |
|
Former Director |
|
|
2021 |
|
|
$ |
30,000 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
30,000 |
|
and President |
|
|
2020 |
|
|
$ |
180,000 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
24,000 |
|
|
$ |
204,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mahmood Khan1 |
|
|
2022 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
866,433 |
|
|
$ |
866,433 |
|
Former Director |
|
|
2021 |
|
|
$ |
95,000 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
95,000 |
|
and CEO |
|
|
2020 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Charles Scott2 |
|
|
2022 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Chair, CEO |
|
|
2021 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
2020 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
S. John Korangy, MD2 |
|
|
2022 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Director, President |
|
|
2021 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
2020 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jeffry Hollis, CPA |
|
|
2022 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Controller, Principal |
|
|
2021 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Accounting Officer |
|
|
2020 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
1 |
Mister Leonzo, Mr. Gunther, Mr. Romagosa and Mr. Khan were all terminated as officers and directors in late April, 2022 by action of the remaining Board of Directors and a majority vote of shareholders, See, Item 9B Change of Management. |
|
2 |
Mister Scott and Dr. Korangy became directors effective January 1, 2022 and became officers (Chairman and President, respectively) on May 2, 2022. Mr. Scott also is majority voting shareholder. They receive no compensation from the Company or the CareClix Companies. |
|
3 |
Mr. Hollis serves as Controller of the CareClix Companies and is compensated by them. For the period from January 1 to May 31, 2022, he received a total of $42,306 in compensation from rhe CareClix Companies. |
The Company has no stock-based option plans in place and has never maintained
any plans that provide for the payment of retirement benefits or benefits that will be paid primarily following retirement including,
but not limited to, tax qualified deferred benefit plans, supplemental executive retirement plans, tax-qualified deferred contribution
plans and nonqualified deferred contribution plans.
Employment Agreements
Mahmood Khan was the CEO of LFER. He had an “at
will” contract with a base salary of $285,000 per year. He was terminated in late April 2022.
There are no other employment agreements; however,
the Company anticipates entering into more employment agreements with key management positions as the Company grows. The Company does
not have a standing compensation committee, audit committee, nomination committee, or committees performing similar functions. We anticipate
that we will form such committees of the Board of Directors once we have a full Board of Directors.
18
Outstanding Equity Awards at Fiscal Year-End
As of May 31, 2022,
and 2021, there were no outstanding options or warrants to purchase, or other instruments convertible into, common equity of the Company,
related to equity awards.
Director Compensation
The Company plans to create an Independent Compensation
committee, reporting to the Board, with a compensation schedule for both Independent Board members as well as Executives of the Company.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The following table sets forth information with respect
to the beneficial ownership of our Common Stock known by us as of May 31, 2022, by
|
· |
each person or entity known by us to be the beneficial owner of more than 5% of our common stock; |
|
· |
each named executive officer; and |
|
· |
all directors and executive officers, as a group |
Except as otherwise indicated, the persons listed
below have sole voting and investment power with respect to all shares of our Common Stock owned by them, except to the extent such power
may be shared with a spouse.
Name and address of beneficial owner1 |
|
Amount of
beneficial ownership2 |
|
Percent of class3 |
Fernando Leonzo, Former Director & Officer |
|
|
4,517,726 |
|
|
|
6.29 |
|
Robert Gunther, Former Director & Officer |
|
|
3,513,458 |
|
|
|
4.89 |
|
John Romagosa, Former Director & Officer |
|
|
6,318,738 |
|
|
|
8.80 |
|
Mahmood Khan, Former Director & Officer |
|
|
9,476,490 |
|
|
|
13.19 |
|
Charles Scott4, Chair and CEO |
|
|
— |
|
|
|
— |
|
John Korangy5, Director and President |
|
|
— |
|
|
|
— |
|
Jeffry Hollis, Controller |
|
|
— |
|
|
|
— |
|
All directors and officers, as a group6 |
|
|
23,816,412 |
|
|
|
33.17 |
|
Shircoo, Inc.
2350 E. Allview Terrace
Los Angeles, CA 90068 |
|
|
14,084,334 |
|
|
|
19.61 |
|
1 The address of the former directors known
to the Company is 1345 6th Ave. 2nd Floor, New York, NY 10015. Although all
1 The address of the former directors known
to the Company is 1345 6th Ave. 2nd Floor, New York, NY 10015. Although all were terminated in late
April 2022, they are considered to be an affiliated group.
The address for the current officers and directors
is c/o the Company at 1270 N. Wickham Road, Suite 13A, No. 1012, Melbourne, FL 32935
2 Beneficial Ownership is determined
in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.
3 The percent of class is based on 71,822,753
shares of common stock issued as of May 31, 2022, plus 5,663,866 shares beneficially owned from the conversion of debt.
4 Mr. Scott holds 5,200,000 shares of Series A Preferred
stock, which represents voting control of the Company.
5 Dr. Korangy currently holds no stock
in the Company.
6 The current officers and directors, as
a group, currently hold no shares of common stock. Former management, as an affiliated group, hold 23,816,412 common shares, representing
33.17 % of common stock issued.
19
Preferred Stock
We are authorized by our Articles of Incorporation
to issue a maximum of 10,000,000 shares of Preferred Stock, $0.001 par value. This Preferred Stock may be in one or more series and containing
such rights, privileges and limitations, including voting rights, conversion privileges and/or redemption rights, as may, from time to
time, be determined by our Board of Directors. Preferred stock may be issued in the future in connection with acquisitions, financings
or such other matters as the Board of Directors deems to be appropriate. In the event that any such shares of Preferred Stock shall be
issued, a Certificate of Designation, setting forth the series of such Preferred Stock and the relative rights, privileges and limitations
with respect thereto, shall be filed. The effect of such Preferred Stock is that our Board of Directors alone, within the bounds and subject
to the federal securities laws and the Delaware Law, may be able to authorize the issuance of Preferred Stock which could have the effect
of delaying, deferring or preventing a change in control of our Company without further action by the stockholders and might adversely
affect the voting and other rights of holders of Common Stock. The issuance of Preferred Stock with voting and conversion rights also
may adversely affect the voting power of the holders of Common Stock, including the loss of voting control to others.
The Board of Directors is expressly vested with the authority to
divide any or all of the Preferred Stock into series and to fix and determine the relative rights and preferences of the shares of each
series so established.
The Board of Directors may exercise this authority
by adopting a resolution setting forth the designation of each series and the number of shares therein and fixing and determining the
relative rights and preferences thereof. The Board of Directors may make any change in the designations, terms, limitations or relative
rights or preferences of any series in the same manner, so long as no shares of such series are outstanding at such time.
Within the limits and restrictions, if any, stated
in any resolution of the Board of Directors originally fixing the number of shares constituting any series, the Board of Directors is
authorized to increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series
subsequent to the issue of shares of such series. In case the number of shares of any series shall be so decreased, the share constituting
such decrease shall resume the status which they had prior to the adoption of the resolution originally fixing the number of shares of
such series.
Series A Preferred Stock
We have designated 5,200,000 shares of Series A Preferred
Stock, par value $0.001 per share. We have 5,200,000 shares of Series A Preferred Stock issued and outstanding. Held by one shareholder
The Series A Preferred Stock does not have
liquidation preferences. The Series A Preferred Stock has 60:1 voting rights, with each share possessing 60 votes. Series A Preferred
shares are not convertible and do not pay dividends.
Series B Preferred Stock
We have designated 100,000 shares of Series B Preferred Stock, par value
$0.001 per share.
As of May 31, 2022, 100,000 shares of our Series B Preferred Stock are
issued and outstanding. The Series B Preferred Stock does not have liquidation preferences. The Series B Preferred Stock has no voting
rights except to the extent it is converted into Common Stock. The holders of Series B Preferred Stock are entitled to a 10% annual cash
dividend paid quarterly.
Series C Preferred Stock
We have designated 2,613,375 shares of
Series C Preferred Stock, par value $0.001 per share. As of May 31, 2022, 2,613,375 Series C Preferred shares were issued. However, 1,528,166
of these shares issued to former directors were issued at par value ($0.001 per share) when the public offer price was $1.00 per share.
The issuance is considered to be without adequate or for no consideration. Any Series C Preferred shares issued for consideration received
of less than $1.00 per share will be considered not validly issued and not outstanding.
The Series C Preferred Stock does
not have liquidation preferences. The Series C Preferred Stock has no voting rights except to the extent that it is converted into common
stock. The holders of Series C Preferred Stock are entitled to a 10% annual cash dividend paid quarterly.
Series D Preferred Stock
We have designated 16,236 shares of Series
D Preferred Stock, par value $0.001 per share. As of May 31, 2022, 16,236 shares of our Series D Preferred Stock are issued and outstanding.
The Series D Preferred Stock does not have
liquidation preferences. The Series D Preferred Stock has no voting rights except to the extent converted into Common Stock. Each share
of the Series D preferred stock converts into 10 shares of common stock. The Series D Preferred Stock pays no dividend.
20
Warrants outstanding
None as of May 31, 2022.
Securities Authorized For Issuance Under Equity
Compensation Plans
We have not adopted any Equity Compensation Plans
as of May 31, 2022.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The current officers and directors of the Company
are involved in other business activities and may, in the future, become involved in additional business opportunities. Currently there
are no employment contracts with the members of the management team. If a specific business opportunity becomes available, such person(s)
may face a conflict in selecting between our business interest and their other business interests. The policy of the Board is that any
personal business or corporate opportunity acquired by an officer or Director must be examined by the Board and turned down by the Board
in a timely basis before an officer or Director can engage or take advantage of a business opportunity which could result in a conflict
of interest.
Director Independence
We are not currently subject to listing requirements
of any national securities exchange or inter-dealer quotation system which has requirements that a majority of the board of directors
be “independent” and, as a result, we are not at this time required to (and we do not) have our Board of Directors comprised
of a majority of “Independent Directors.”
Our Board of Directors has considered the independence
of its directors in reference to the definition of “independent director” established by the NASDAQ Marketplace Rule 5605(a)(2).
In doing so, the Board of Directors has reviewed all commercial and other relationships of each director in making its determination as
to the independence of its directors.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Audit Fees
Effective March 16, 2020, our Board of Directors appointed
Boyle CPA LLC (“Boyle”) as our independent registered public accounting firm, to audit our financial statements for the years
ended May 31, 2022 and 2021.
The aggregate fees billed to the Company for services
rendered in connection with the years ended May 31, 2022 and 2020 are set forth in the table below:
Fee category |
|
2022 |
|
2021 |
Audit fees (1 ) |
|
|
50,000 |
|
|
$ |
45,000 |
|
Audit related (2) |
|
|
15,000 |
|
|
|
15,000 |
|
Tax fees |
|
|
— |
|
|
|
— |
|
Total fees |
|
|
65,000 |
|
|
$ |
60,000 |
|
___________
(1) |
Audit fees consist of fees incurred for professional services rendered for the audit of financial statements, for reviews of our interim financial statements included in our quarterly reports on Form 10-Q, Form 10-K and for services that are normally provided in connection with statutory or regulatory filings or engagements. Audit fees do not include any fees for the audit of the CareClix Companies, as part of the anticipated acquisition which has now been abandoned. Any audit fees for the CareClix Companies will be billed to and paid by the CareClix Companies. |
(2) |
Audit related fees consist of fees incurred for professional services related to the acquisition audit of SmartAxiom, Inc. |
Audit Committee’s Pre-Approval
Practice
We currently do not have an audit committee. Our board
of directors has approved the services described above.
21
PART IV - FINANCIAL
INFORMATION
|
|
Page |
|
|
|
|
|
Report of Independent Registered Public Accounting Firm |
|
F-1 |
|
|
|
|
|
Consolidated Balance Sheets at May 31, 2022 and 2021 |
|
F-3 |
|
|
|
|
|
Consolidated Statements of Operations for the years ended May 31, 2022 and 2021 |
|
F-4 |
|
|
|
|
|
Consolidated Statements of Changes in Stockholders’ Deficiency for the years ended May 31, 2022 and 2021 |
|
F-5 |
|
|
|
|
|
Consolidated Statements of Cash Flows for the years ended May 31, 2022 and 2021 |
|
F-6 |
|
|
|
|
|
Notes to Consolidated Financial Statements |
|
F-8 |
|
22
Boyle CPA, LLC
Certified Public Accountants & Consultants
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
To the Shareholders and Board of Directors of Life on Earth, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets of
Life on Earth, Inc. (the “Company”) as of May 31, 2022 and 2021, the related statements of operations, stockholders’
deficiency, and cash flows for each of the two years in the period ended May 31, 2022, and the related notes (collectively referred to
as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of May 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in
the period ended May 31, 2022, in conformity with accounting principles generally accepted in the United States of America.
Substantial Doubt About the Company’s
Ability to Continue as a Going Concern
The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company’s
continuing operating losses, negative working capital and negative cash flows from operating activities raise substantial doubt about
its ability to continue as a going concern for a period of one year from the issuance of the consolidated financial statements. Management’s
plans are also described in Note 2. The consolidated financial statements do not include adjustments that might result from the outcome
of this uncertainty.
Basis of Opinion
These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our
audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)
and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with standards
of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to fraud or error. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
F-1
Critical Audit Matters
Critical audit
matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved
our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters. The
communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are
not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or
disclosures to which they relate.
Accounting for the Smart Axiom, Inc. (“SA”)
Acquisition
As discussed in Note 5 to the consolidated financial
statements, on May 2, 2022, the Company entered into a stock purchase agreement with SmartAxiom, Inc. (“SA”) and its shareholders
providing for the Company to purchase of all the outstanding common stock shares of SA. The Agreement was supplemented by First and Second
Addendum Agreements, dated April 30, 2021, and May 11, 2021, respectively. The total purchases price was $5,044,127, based upon the fair
value of the common and preferred stock to be issued and the earn out provisions. The Company allocated this fair value to the assets
and liabilities, with $5,177,643 allocated to capitalized software, patents, and customer lists. The Company estimated the useful lives
of these intangible assets to be five years.
We identified the accounting considerations and related
valuations as a critical audit matter. The principal considerations for our determination were the accounting and valuation considerations
in determining the valuation of the consideration given, the allocation of the purchase price to the acquired assets and liabilities,
and the subsequent valuation of the acquired intangible assets. Auditing these elements is especially challenging and requires auditor
judgement due to the nature and extent of audit effort required to address these matters, including the extent of specialized skill or
knowledge needed.
Our audit procedures related to the acquisition and
disposition of SA, included the following, among others: (1) evaluating the relevant terms and conditions of the acquisition agreement,
(2) assessing the valuation of the consideration given by the Company and the allocation of the fair value to the assets and liabilities
of SA, (3) independently assessing the valuations determined by Management, and (4) recomputing the carrying values of the acquired intangible
assets.
/s/ Boyle CPA, LLC
We have served as the Company’s auditor since 2020
|
|
|
331 Newman Springs Road |
|
P (732) 822-4427 |
Building 1, 4th Floor, Suite 143 |
|
F (732) 510-0665 |
Red Bank, NJ 07701
|
|
|
F- 2
Life On Earth, Inc. |
Consolidated Balance Sheets |
|
|
|
|
|
|
|
May 31, |
|
May 31, |
|
|
2022 |
|
2021 |
ASSETS |
Current Assets |
|
|
|
|
|
|
|
|
Other current receivable |
|
|
— |
|
|
|
70,000 |
|
Current assets of discontinued operations |
|
|
— |
|
|
|
43,656 |
|
Total current assets |
|
|
— |
|
|
|
113,656 |
|
|
|
|
|
|
|
|
|
|
Other Assets |
|
|
|
|
|
|
|
|
Other assets of discontinued operations |
|
|
— |
|
|
|
5,105,687 |
|
|
|
|
— |
|
|
|
|
|
Total Assets |
|
$ |
— |
|
|
$ |
5,219,343 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' DEFICIENCY |
Current Liabilities |
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses |
|
$ |
458,621 |
|
|
$ |
914,774 |
|
Accrued dividends payable on preferred shares |
|
|
158,000 |
|
|
|
9,750 |
|
Accrued contingent liability due related parties |
|
|
111,225 |
|
|
|
1,144,354 |
|
Convertible Note payable to L & H, Inc. |
|
|
176,239 |
|
|
|
110,000 |
|
Accrued contingent liability for the purchase of Smart Axion |
|
|
— |
|
|
|
5,044,127 |
|
Contingent liability |
|
|
— |
|
|
|
415,227 |
|
Derivative liability |
|
|
— |
|
|
|
110,588 |
|
Note payable |
|
|
30,000 |
|
|
|
30,000 |
|
Notes payable - due to CareClix, Inc. |
|
|
108,258 |
|
|
|
|
|
Notes payable - related party, net of unamortized deferred financing costs of $15,522 and $0 as of May 31, 2022 and May 31, 2021, respectively |
|
|
112,076 |
|
|
|
58,491 |
|
Convertible notes payable, net of unamortized deferred financing costs of $6,157 and $29,633 as of May 31, 2022 and May 31, 2021, respectively |
|
|
549,523 |
|
|
|
1,822,964 |
|
Current liabilities of discontinued operations |
|
|
— |
|
|
|
220,860 |
|
Total current liabilities |
|
|
1,703,942 |
|
|
|
9,881,134 |
|
|
|
|
|
|
|
|
|
|
Total Liabilities |
|
|
1,703,942 |
|
|
|
9,881,134 |
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders' Deficiency |
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value; 10,000,000 shares authorized, |
|
|
|
|
|
|
|
|
Series A Preferred Stock, 5,200,000 and 1,200,000 shares issued and outstanding as of May 31, 2022 and May 31, 2021, respectively |
|
|
5,200 |
|
|
|
1,200 |
|
Series B Preferred Stock, 100,000 and 100,000 shares issued and outstanding as of May 31, 2022 and May 31, 2021, respectively |
|
|
100 |
|
|
|
100 |
|
Series C Preferred Stock, 2,613,375 and 290,000 shares issued and outstanding as of May 31, 2022 and May 31, 2021, respectively |
|
|
2,614 |
|
|
|
290 |
|
Series D Preferred Stock, 16,236 and 210,000 shares issued and outstanding as of May 31, 2022 and May 31, 2021, respectively |
|
|
16 |
|
|
|
210 |
|
Common stock, $0.001 par value; 500,000,000 shares authorized, 71,822,753 and 29,548,676 shares issued and outstanding as of May 31, 2022 and May 31, 2021, respectively |
|
|
71,822 |
|
|
|
29,549 |
|
Treasury stock |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
21,457,379 |
|
|
|
13,942,216 |
|
Accumulated deficit |
|
|
(23,241,073 |
) |
|
|
(18,635,356 |
) |
Total Stockholders' Deficiency |
|
|
(1,703,942 |
) |
|
|
(4,661,791 |
) |
|
|
|
|
|
|
|
|
|
Total Liabilities and Stockholders' Deficiency |
|
$ |
— |
|
|
$ |
5,219,343 |
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements. |
F-3
Life On Earth, Inc. |
Consolidated Statements of Operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended May 31, |
|
|
2022 |
|
2021 |
|
|
|
|
|
Sales |
|
$ |
— |
|
|
$ |
— |
|
Cost of goods sold |
|
|
— |
|
|
|
— |
|
Gross profit |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
Expenses: |
|
|
|
|
|
|
|
|
Professional fees |
|
|
380,274 |
|
|
|
319,955 |
|
Officers’ compensation |
|
|
1,545,526 |
|
|
|
185,000 |
|
Salaries and benefits |
|
|
— |
|
|
|
16,935 |
|
General and administrative |
|
|
22,421 |
|
|
|
62,402 |
|
Amortization |
|
|
— |
|
|
|
79,272 |
|
Total expenses |
|
|
1,948,221 |
|
|
|
663,564 |
|
|
|
|
|
|
|
|
|
|
Loss from operations |
|
|
(1,948,221 |
) |
|
|
(663,564 |
) |
|
|
|
|
|
|
|
|
|
Other income and (expenses): |
|
|
|
|
|
|
|
|
Change in fair value of contingent consideration |
|
|
352,227 |
|
|
|
(357,955 |
) |
Change in fair value of derivative liability |
|
|
110,588 |
|
|
|
36,127 |
|
Interest and financing costs |
|
|
(502,832 |
) |
|
|
(423,546 |
) |
|
|
|
|
|
|
|
|
|
Loss from continuing operations |
|
|
(1,988,237 |
) |
|
|
(1,408,938 |
) |
Loss on discontinued operations |
|
|
(1,221,091 |
) |
|
|
(25,135 |
) |
Loss on sale of subsidiary |
|
|
(1,135,279 |
) |
|
|
— |
|
Loss on disposal of subsidiaries |
|
|
(261,110 |
) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(4,605,717 |
) |
|
$ |
(1,434,073 |
) |
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share from continuing operations |
|
$ |
(0.03 |
) |
|
$ |
(0.07 |
) |
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share on discontinued operations |
|
$ |
(0.04 |
) |
|
$ |
(0.00 |
) |
|
|
|
|
|
|
|
|
|
Basic and diluted weighted average number |
|
|
|
|
|
|
|
|
of shares outstanding |
|
|
58,393,543 |
|
|
|
21,123,838 |
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements. |
F- 4
Life On Earth, Inc. |
Cosolidated Statements of Stockholders' Deficiency |
For the years ended May 31, 2022 and May 31, 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series A Preferred |
|
Series B Preferred |
|
Series C Preferred |
|
Series D Preferred |
|
Common Stock |
|
Additional |
|
Accumulated |
|
Total Stockholders' |
|
|
Shares |
|
Amount |
|
Shares |
|
Amount |
|
Shares |
|
Amount |
|
Shares |
|
Amount |
|
Shares |
|
Amount |
|
Paid in capital |
|
Deficit |
|
Deficiency |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - June 1, 2020 |
|
|
1,200,000 |
|
|
$ |
1,200 |
|
|
|
— |
|
|
$ |
— |
|
|
|
— |
|
|
$ |
— |
|
|
|
— |
|
|
$ |
— |
|
|
|
13,081,380 |
|
|
$ |
13,081 |
|
|
$ |
12,901,158 |
|
|
$ |
(17,201,283 |
) |
|
$ |
(4,285,844 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale of Series B preferred shares |
|
|
|
|
|
|
|
|
|
|
100,000 |
|
|
|
100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
99,900 |
|
|
|
|
|
|
|
100,000 |
|
Sale of Series C preferred shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
290,000 |
|
|
|
290 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
289,710 |
|
|
|
|
|
|
|
290,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of Series D preferred shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
210,000 |
|
|
|
210 |
|
|
|
|
|
|
|
|
|
|
|
(210 |
) |
|
|
|
|
|
|
— |
|
Issuance of common shares for convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,801,203 |
|
|
|
14,801 |
|
|
|
486,969 |
|
|
|
|
|
|
|
501,770 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common shares for finance costs related to convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,297,500 |
|
|
|
1,298 |
|
|
|
136,615 |
|
|
|
|
|
|
|
137,913 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common shares for services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
368,593 |
|
|
|
369 |
|
|
|
28,074 |
|
|
|
|
|
|
|
28,443 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1,434,073 |
) |
|
|
(1,434,073 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance - May 31, 2021 |
|
|
1,200,000 |
|
|
$ |
1,200 |
|
|
|
100,000 |
|
|
$ |
100 |
|
|
|
290,000 |
|
|
$ |
290 |
|
|
|
210,000 |
|
|
$ |
210 |
|
|
|
29,548,676 |
|
|
$ |
29,549 |
|
|
$ |
13,942,216 |
|
|
$ |
(18,635,356 |
) |
|
$ |
(4,661,791 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of Series A Preferred shares for CareClix Acquisition |
|
|
4,000,000 |
|
|
|
4,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,000 |
|
Sale of Series C preferred shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
138,485 |
|
|
|
139 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
158,341 |
|
|
|
|
|
|
|
158,480 |
|
Issuance of Series C preferred shares for convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
706,724 |
|
|
|
707 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
686,038 |
|
|
|
|
|
|
|
686,745 |
|
Conversion of Series C Preferred shares to Common |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(50,000 |
) |
|
|
(50 |
) |
|
|
|
|
|
|
|
|
|
|
525,000 |
|
|
|
525 |
|
|
|
(475 |
) |
|
|
|
|
|
|
— |
|
Cancellation of Series D Preferred shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(193,764 |
) |
|
|
(194 |
) |
|
|
|
|
|
|
|
|
|
|
194 |
|
|
|
|
|
|
|
0 |
|
Issuance of common shares for SA Acquisition |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,000,000 |
|
|
|
13,000 |
|
|
|
2,717,000 |
|
|
|
|
|
|
|
2,730,000 |
|
Common shares issued for SA acquisition that were returned and cancelled |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,974,695 |
) |
|
|
(7,975 |
) |
|
|
(526,330 |
) |
|
|
|
|
|
|
(534,305 |
) |
Issuance of common shares for convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,685,393 |
|
|
|
14,685 |
|
|
|
883,035 |
|
|
|
|
|
|
|
897,720 |
|
Sale of common shares to related parties at $0.001 per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,503,177 |
|
|
|
12,503 |
|
|
|
952,742 |
|
|
|
|
|
|
|
965,245 |
|
Issuance of common shares to related parties as consideration at $0.001 per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,056,332 |
|
|
|
3,056 |
|
|
|
232,893 |
|
|
|
|
|
|
|
235,949 |
|
Sale of Series C preferred shares to related parties at $0.001 per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,528,166 |
|
|
|
1,528 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,526,640 |
|
|
|
|
|
|
|
1,528,168 |
|
Issuance of common shares as consideration shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,674,231 |
|
|
|
2,674 |
|
|
|
238,115 |
|
|
|
|
|
|
|
240,789 |
|
Issuance of common shares for JCG contingency shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
572,727 |
|
|
|
573 |
|
|
|
62,427 |
|
|
|
|
|
|
|
63,000 |
|
Issuance of common shares for services at prices ranging from $0.07 to $0.156 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,581,912 |
|
|
|
2,582 |
|
|
|
236,578 |
|
|
|
|
|
|
|
239,160 |
|
Issuance of common shares for settlement of legal claim |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500,000 |
|
|
|
500 |
|
|
|
49,500 |
|
|
|
|
|
|
|
50,000 |
|
Issuance of common shares for settlement of legal claim |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
150,000 |
|
|
|
150 |
|
|
|
14,850 |
|
|
|
|
|
|
|
15,000 |
|
Net deficiency of disposed subsidiaries |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
287,615 |
|
|
|
|
|
|
|
287,615 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4,605,717 |
) |
|
|
(4,605,717 |
) |
Balance - May 31, 2022 |
|
|
5,200,000 |
|
|
$ |
5,200 |
|
|
|
100,000 |
|
|
$ |
100 |
|
|
|
2,613,375 |
|
|
$ |
2,614 |
|
|
|
16,236 |
|
|
$ |
16 |
|
|
|
71,822,753 |
|
|
$ |
71,822 |
|
|
$ |
21,461,379 |
|
|
$ |
(23,341,073 |
) |
|
$ |
(1,703,942 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed financial statements. |
F-5
Life On Earth, Inc.
Consolidated Statements of Cash
Flows
|
|
|
|
|
|
|
|
|
|
|
For the years ended May 31, |
|
|
2022 |
|
2021 |
|
|
|
|
|
Cash Flows From Operating Activities |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(4,605,717 |
) |
|
$ |
(1,434,073 |
) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
|
|
|
|
|
|
|
|
Stock based compensation |
|
|
239,160 |
|
|
|
28,443 |
|
Stock based compensation - related parties |
|
|
2,715,331 |
|
|
|
— |
|
Depreciation and amortization |
|
|
— |
|
|
|
79,273 |
|
Loss on disposal of subsidiaries |
|
|
261,110 |
|
|
|
— |
|
Amortization of interest and financing costs |
|
|
64,214 |
|
|
|
— |
|
Share based finance costs |
|
|
240,790 |
|
|
|
219,571 |
|
Provision for bad debts |
|
|
— |
|
|
|
990 |
|
Change in fair value of contingent liability |
|
|
(352,227 |
) |
|
|
357,954 |
|
Change in fair value of derivative liability |
|
|
(110,588 |
) |
|
|
(36,127 |
) |
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
(Increase) decrease in: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
— |
|
|
|
(990 |
) |
Prepaid expenses and other current assets |
|
|
— |
|
|
|
149 |
|
Other current receivable |
|
|
70,000 |
|
|
|
(70,000 |
) |
Increase (decrease) in: |
|
|
|
|
|
|
|
|
Accounts payable, accrued expenses and contingent liability |
|
|
(164,851 |
) |
|
|
467,203 |
|
Accrued contingent liability due related parties |
|
|
(727,002 |
) |
|
|
— |
|
|
|
|
|
|
|
|
|
|
Cash used by operating activities of continuing operations |
|
|
(2,369,780 |
) |
|
|
(387,607 |
) |
Cash used by operating activities of discontinued operations |
|
|
2,106,370 |
|
|
|
(59,764 |
) |
Cash used by operating activities |
|
|
(263,410 |
) |
|
|
(447,371 |
) |
|
|
|
|
|
|
|
|
|
Cash Flows From Investing Activities |
|
|
|
|
|
|
|
|
Acquisition of subsidiary, net cash acquired |
|
|
— |
|
|
|
39,878 |
|
Cash used by investing activities |
|
|
— |
|
|
|
39,878 |
|
|
|
|
|
|
|
|
|
|
Cash Flows From Financing Activities |
|
|
|
|
|
|
|
|
Proceeds of notes payable - related parties |
|
|
48,636 |
|
|
|
5,631 |
|
Repayment of notes payable - related parties |
|
|
(2,250 |
) |
|
|
(9,000 |
) |
Proceeds of notes payable |
|
|
— |
|
|
|
30,000 |
|
Repayment of notes payable |
|
|
— |
|
|
|
(1,288 |
) |
Proceeds of convertible notes payable |
|
|
38,580 |
|
|
|
— |
|
Repayment of convertible notes payable |
|
|
(100,000 |
) |
|
|
— |
|
Proceeds of notes payable - CareClix |
|
|
105,933 |
|
|
|
|
|
Proceeds from lines of credit, net of financing costs |
|
|
— |
|
|
|
19,426 |
|
Repayment of lines of credit |
|
|
— |
|
|
|
(31,107 |
) |
Proceeds from sales of Series B preferred stock |
|
|
— |
|
|
|
100,000 |
|
Proceeds from sales of Series C preferred stock |
|
|
158,480 |
|
|
|
290,000 |
|
Proceeds from sales of Series C preferred stock to related parties |
|
|
1,528 |
|
|
|
|
|
Proceeds from sales of common stock to related parties |
|
|
12,503 |
|
|
|
|
|
Cash (used)/provided by financing activities |
|
|
263,410 |
|
|
|
403,662 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Increase (decrease) in Cash and Cash Equivalents |
|
|
— |
|
|
$ |
(3,831 |
) |
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents - beginning |
|
|
— |
|
|
|
3,831 |
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents - end |
|
$ |
— |
|
|
$ |
— |
|
F- 6
|
|
|
|
|
|
|
|
|
Supplemental Disclosures of Cash Flow Information |
|
|
|
|
|
|
|
|
Cash paid for: |
|
|
|
|
|
|
|
|
Interest |
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Noncash investing and financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common shares for services at prices ranging from $0.07 to $0.156 |
|
$ |
239,160 |
|
|
$ |
28,443 |
|
|
|
|
|
|
|
|
|
|
Common stock issued for convertible debt |
|
$ |
897,720 |
|
|
$ |
501,770 |
|
|
|
|
|
|
|
|
|
|
Series C preferred shares issued for convertible debt |
|
$ |
686,745 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Common stock issued with convertible debt as financing cost |
|
$ |
240,789 |
|
|
$ |
137,913 |
|
|
|
|
|
|
|
|
|
|
Common stock issued as consideration to related parties |
|
$ |
235,949 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Common stock issued for settlement of legal claims |
|
$ |
65,000 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Derivative liability associated with convertible debt |
|
$ |
— |
|
|
$ |
110,588 |
|
|
|
|
|
|
|
|
|
|
Common stock issued for JCG acquisition contingency shares |
|
$ |
63,000 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Common stock issued for SA Acquisition |
|
$ |
2,730,000 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Common stock returned and cancelled |
|
$ |
(534,305 |
) |
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
Series A preferred shares issued for CareClix acquisition |
|
$ |
4,000 |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed financial statements. |
F- 7
Life On Earth, Inc.
Notes to Consolidated Financial Statements
Note 1. NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES
Nature of Operations and Basis of Presentation
Company History
Life on Earth, Inc. (“LFER” or “the
Company”) was incorporated in Delaware in April 2013.
The accompanying consolidated financial statements
have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
The accompanying consolidated financial statements
include the financial statements of the Company and its former wholly owned subsidiaries, Smart Axiom, Inc. On March 8, 2022, we executed
a Stock Purchase and Mutual Release Agreement (the “Agreement”) under which we divested our ownership of SmartAxiom, Inc.
(“SA”), effective December 31, 2021. As a result, the accompanying consolidated financial statements include the financial
operations of SA for the period June 1, 2021 through December 31, 2021, as discontinued operations. During the fiscal year ended May 31,
2022, our Board of Directors also resolved to dispose of our non-operating subsidiaries Victoria’s Kitchen and The Chill Group,
for a net loss of $261,110.
The Company is a public holding company operating
in the public holding company market. All prior operations of the Company have been discontinued.
On May 11, 2021, the Company acquired SmartAxiom with
all their assets including intellectual properties, Patents and core Internet of Things (IoT) software that enables securing sensor devices
and communication to the cloud-based software. The agreed purchase price was $6,250,000 paid as follows: (a) $1,950,000 by issuing 13,000,000
shares of the Company’s common stock, upon closing; (b) $2,100,000 by issuing 210,000 shares of the Company’s Series D convertible
preferred shares (each share of the Company’s Series D convertible preferred is convertible into 10 shares of the Company’s
common stock); and, (c) $2,200,000 to be paid pursuant to a full earnout based on SmartAxiom GAAP revenue recognition in the amount of
$1,500,000 within the first eighteen months after closing date of the acquisition. The earnout will be prorated based on the SmartAxiom
revenues received over an eighteen-month period.
On December 17, 2021, the Company entered into a Stock
Purchase Agreement (“SPA”) with CareClix Holdings, Inc., a Florida corporation (“SOLI”) to acquire 100% ownership
of the four subsidiaries of SOLI, which included CareClix, Inc., a Virginia corporation, CareClix Services, Inc., a Florida corporation,
MyCareClix, Inc., a Florida corporation, and CareClix RPM, Inc., a Florida corporation (collectively, the “CareClix Group”).
Effective December 31, 2021, the Company determined
that its subsidiaries Victoria’s Kitchen and The Chill Group both of which had been inactive for some time, should be discontinued,
resulting in a loss for the period ended February 28, 2022.
F-8
On March 8, 2022, the Company divested its ownership
of the former subsidiary SmartAxiom, Inc. The Company executed a Stock Purchase and Mutual Release Agreement under which the Company divested
its ownership of the former subsidiary SmartAxiom, Inc., effective December 31, 2021. The decision was made due to certain critical factors
including, but not limited to, 1) the focus of the Company exclusively on the medical technology industry, 2) the slow progress of performance
from SA, and 3) redeployment of resources to the growth potential of the CareClix group of companies. Under the Agreement, the Company
agreed to transfer all ownership in SA to Amit Biyani in exchange for Mr. Biyani’s agreement to return for cancellation: (ii) 7,974,695
shares of common stock; and (ii) 128,822 shares of Series D Preferred Stock. In addition, SA and Mr. Biyani agreed to arrange for the
return and cancellation of the remaining outstanding 64,942 shares of Series D Preferred Stock currently held by other former shareholders
of SA. By agreement among the parties, the divestiture of SA was deemed legally effective as of December 31, 2021. The Agreement also
contains mutual releases amongst the parties. In connection with the Agreement, SA issued to the Company an 8% Unsecured Convertible Note
in the amount of $250,000 dated December 31, 2021 (the “Note”). The Note bears interest at a rate of 8 percent per year, with
all principal and interest due on or before February 28, 2024. All unpaid principal and interest owing under the Note may, at the Company’s
option, be converted in whole into a number of fully paid and non-assessable shares of common stock of SA having a value equal to the
Note balance, converted at an assumed total valuation of SA of $6,250,000 on a fully diluted basis. At May 31, 2022, the Company has determined
that collection on the Note is doubtful and accordingly, has established an allowance for doubtful accounts in the amount of $250,000
by recording a charge to discontinued operation for the year ended May 31, 2022.
On May 2, 2022, the Company adopted an Amended Management
Agreement which allowed the Final Closing of the acquisition with the May 31, 2022, transaction drop-dead date extended. On September
15, 2022, former management filed an action to restore themselves as directors, to rescind the Amended Management Operating Agreement
and to terminate the CareClix Companies’ acquisition. Current management agreed, the Amended Management Operating Agreement of May
2, 2022, was rescinded as of May 2, 2022, the drop-dead date became effective, and the CareClix Companies are no longer part of the Company
Life On Earth, Inc is a Delaware corporation headquartered
in Melbourne, Florida.
Revenue Recognition
The accompanying consolidated financial statements
have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In
May 2014, the FASB issued guidance codified in ASC 606 which amends the guidance in former ASC 605, “Revenue Recognition.”
The core principle of the standard is to recognize revenue when control of the promised goods or services is transferred to customers
in an amount that reflects the consideration expected to be received for those goods or services. The standard also requires additional
disclosures around the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.
The Company recognizes revenue from product sales
or services rendered under ASC 606, which directs that revenue should be recognized when the promised goods or services are transferred
to the customer. The amount of revenue recognized should equal the total consideration expected to be received in return for the goods
or services. ASC 606 creates a five-step approach that should be applied when determining the amount and timing of revenue recognition.
• Step 1: Identify the contract with a customer
• Step 2: Identify the performance obligations
in the contract
• Step 3: Determine the transaction price
• Step 4: Allocate the transaction price to
the performance obligations in the contract
• Step 5: Recognize revenue when (or as) the
entity satisfies a performance obligation
F-9
Use of Estimates
The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent assets and liabilities at the dates of the consolidated balance sheets and the reported amounts of revenues
and expenses during the reporting periods. Actual results could differ from those estimates.
Reclassifications
Certain reclassifications have been made in prior
year’s financial statements to conform to classifications used in the current year.
Net Loss Per Common Share
Basic loss per share is calculated by dividing net
loss by the weighted average number of common shares outstanding for the period. Diluted loss per share is calculated by dividing net
loss by the weighted average number of common shares and dilutive common stock equivalents outstanding. During periods in which the Company
incurs losses, common stock equivalents, if any, are not considered, as their effect would be anti-dilutive. As of May 31, 2022, and 2021,
respectively, warrants and convertible notes payable could be converted into approximately 2,283,000 and 23,088,000 shares of common stock,
respectively.
Income Taxes
The Company utilizes the accrual method of accounting
for income taxes. Under the accrual method, deferred tax assets and liabilities are determined based on the differences between the financial
reporting basis and the tax basis of the assets and liabilities and are measured using enacted tax rates and laws that will be in effect
when the differences are expected to reverse. An allowance against deferred tax assets is recognized when it is more likely than not that
such tax benefits will not be realized.
The Company recognizes the financial statement benefit
of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination.
For tax positions meeting a “more-likely-than-not” threshold, the amount recognized in the consolidated financial statements
is the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial
statement benefit is recognized. The Company recognizes interest and penalties, if any, related to uncertain tax positions in income tax
expense. The Company did not have any unrecognized tax benefits as of May 31, 2022 and does not expect this to change significantly over
the next 12 months.
F-10
Accounting for Equity Awards
The cost of services received in exchange for an award
of equity instruments related to employees and non-employees is based on the grant-date fair market value of the award and allocated over
the requisite service period of the award.
Cash and Cash Equivalents
The Company considers only those investments which
are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to be cash equivalents.
At May 31, 2022 and 2021, respectively, the Company
had cash and cash equivalents of $0 and $34,629, respectively, comprised of funds in checking accounts, savings accounts and money market
funds. The Company’s cash and cash equivalents at May 31, 2021 were included in current assets of discontinued operations.
Accounts Receivable
Our accounts receivable balance primarily includes
balances from trade sales to distributors and retail customers. The allowance for doubtful accounts is our best estimate of the amount
of probable credit losses in our existing accounts receivable. We determine the allowance for doubtful accounts based primarily on historical
write-off experience. Account balances that are deemed uncollectible, are charged off against the allowance after all means of collection
have been exhausted and the potential for recovery is considered remote. The Company extends credit to its customers in the normal course
of business and performs ongoing credit evaluations of its customers. A significant change in demand for certain products as compared
to forecasted amounts may result in recording additional provisions for obsolete inventory. Provisions for obsolete or excess inventory
are recorded as cost of goods sold.
As of May 31, 2022, and May 31, 2021, the allowance
for doubtful accounts was $0 and $0, respectively.
Inventory
As a holding company with no operations, there are
no inventories.
Intangible Assets
The Company's
intangible assets include developed technology, customer relationships, sales systems, and tradenames and were acquired in a purchase
business combination. The Company carries these intangibles at cost, less accumulated amortization. Amortization is recorded on a straight-line
basis over the estimated useful lives of the respective assets, which is estimated to be 5 years.
Costs that are
related to the conceptual formulation and design of licensed software programs are expensed as incurred to research, development and engineering
expense; costs that are incurred to produce the finished product after technological feasibility has been established are capitalized
as an intangible asset. Capitalized amounts are amortized on a straight-line basis over periods ranging up to five years. The company
performs periodic reviews to ensure that unamortized program costs remain recoverable from future revenue.
There were no indefinite-lived
intangible assets as of May 31, 2022 or 2021.
The Company reviews its finite-lived
intangible and other long-lived assets whenever events or changes in circumstances indicate that the carrying amount of such assets may
not be recoverable. The carrying amount of an asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to
result from the use and eventual disposition of the asset. Fair value of finite-lived intangible assets and property and equipment is
based on various valuation techniques. If the carrying amount of an asset or group of assets exceeds its net realizable value, the asset
will be written down to its fair value.
Goodwill
Goodwill is deemed to have an indefinite life, and
accordingly, is not amortized, but evaluated annually (or more frequently if events or changes in circumstances indicate the carrying
value may not be recoverable) for impairment. The most significant assumptions, which are used in this test, are estimates of future cash
flows. If these assumptions differ significantly from actual results, impairment charges may be required in the future.
F-11
Advertising
Advertising and promotion costs are expensed as incurred.
Advertising and promotion expense amounted to approximately $14,193 and $15,449 for the years ended May 31, 2022 and 2021, respectively.
Business combination
GAAP requires that all business combinations not involving
entities or businesses under common control be accounted for under the acquisition method. The Company applies ASC 805, “Business
combinations”, whereby the cost of an acquisition is measured as the aggregate of the fair values at the date of exchange of the
assets given, liabilities incurred, and equity instruments issued. The costs directly attributable to the acquisition are expensed as
incurred. Identifiable assets, liabilities and contingent liabilities acquired or assumed are measured separately at their fair value
as of the acquisition date, irrespective of the extent of any non-controlling interests. The excess of (i) the total of cost of acquisition,
fair value of the non-controlling interests and acquisition date fair value of any previously held equity interest in the acquiree over
(ii) the fair value of the identifiable net assets of the acquiree is recorded as goodwill. If the cost of acquisition is less than the
fair value of the net assets of the subsidiary acquired, the difference is recognized directly in the consolidated statements of operations
and comprehensive income.
The determination and allocation of fair values to
the identifiable assets acquired and liabilities assumed is based on various assumptions and valuation methodologies requiring considerable
management judgment. The most significant variables in these valuations are discount rates, terminal values, the number of years on which
to base the cash flow projections, as well as the assumptions and estimates used to determine the cash inflows and outflows. Management
determines discount rates to be used based on the risk inherent in the related activity’s current business model and industry comparisons.
Terminal values are based on the expected life of products and forecasted life cycle and forecasted cash flows over that period. The Company’s
estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and,
as a result, actual results may differ from estimates. Any changes to provisional amounts identified during the measurement period are
recognized in the reporting period in which the adjustment amounts are determined.
Deferred Finance Cost
Deferred financing costs or debt issuance costs are
costs associated with issuing debt, such as various fees and commissions paid to investment banks, law firms, auditors, regulators, and
so on. Since these payments do not generate future benefits, they are treated as a contra debt account. The costs are capitalized, reflected
in the balance sheet as a contra long-term liability, and amortized using the effective interest method or over the finite life of the
underlying debt instrument, if below de minimis.
Derivative Liability
The Company accounts for certain instruments, which
do not have fixed settlement provisions, as derivative instruments in accordance with FASB ASC 815-40, Derivative and Hedging –
Contracts in Entity’s Own Equity. This is due to the conversion features of certain convertible notes payable being tied to the
market value of our common stock. As such, our derivative liabilities are initially measured at fair value on the contract date and are
subsequently re-measured to fair value at each reporting date. Changes in estimated fair value are recorded as non-cash adjustments within
other income (expenses), in the Company’s accompanying Condensed Statements of Operations.
F-12
Fair Value Measurements
We categorize our financial instruments into a three-level
fair value hierarchy that prioritize the inputs to valuation techniques used to measure fair value. The fair value hierarchy gives the
highest priority to quoted prices in active markets for identical assets (Level 1) and the lowest priority to unobservable inputs (Level
3). If the inputs used to measure fair value fall within different levels of the hierarchy, the category level is based on the lowest
priority level input that is significant to the fair value measurement of the instrument. Financial assets recorded at fair value on our
consolidated balance sheets are categorized as follows:
Level 1 inputs—Observable inputs that reflect
quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2 inputs—Significant other observable
inputs (e.g., quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not
active, inputs other than quoted prices that are observable such as interest rate and yield curves, and market-corroborated inputs).
Level 3 inputs—Unobservable inputs for the asset
or liability, which are supported by little or no market activity and are valued based on management’s estimates of assumptions
that market participants would use in pricing the asset or liability.
Recent Accounting Pronouncements
Management does not believe that any recently issued
accounting pronouncements would have a material effect on the accompanying consolidated financial statements.
Note 2 - BASIS OF REPORTING AND GOING CONCERN
The accompanying consolidated financial statements
have been prepared assuming the Company will continue as a going concern, which contemplates the recoverability of assets and the satisfaction
of liabilities in the normal course of business.
Several conditions and events may cast substantial
doubt about the Company’s ability to continue as a going concern. The Company has incurred net losses from inception of more than
$23,000,000, has no cash, and no current business operations.
Note 3 - CONCENTRATIONS
Concentration of Credit Risk
The Company’s financial instruments that are
exposed to concentrations of credit risk consist primarily of cash and accounts receivable. The Company places its cash with high quality
credit institutions. At times, balances may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit.
Cash in banks is insured by the FDIC up to $250,000 per institution, per entity. The Company routinely assesses the financial strength
of its customers and, as a consequence, believes that its account receivable credit risk exposure is limited.
Sales and Accounts Receivable
During the years ended May 31, 2022 and May 31, 2021,
there were no sales.
F-13
Note 4 – FAIR VALUE MEASUREMENTS
We follow the provisions of ASC 820-10, Fair
Value Measurements and Disclosures Topic, or ASC 820-10, for our financial assets and liabilities. ASC 820-10 provides a framework
for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. ASC 820-10 defines fair value
as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous
market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes
a fair value hierarchy, which requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable
inputs when measuring fair value.
Financial assets and liabilities recorded on the accompanying
consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:
Level 1 – Unadjusted quoted prices in active
markets that are accessible to the reporting entity at the measurement date for identical assets and liabilities.
Level 2 – Inputs other than quoted prices in
active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term
of the asset or liability. Level 2 – Inputs include the following:
|
· |
Quoted prices for similar assets and liabilities in active markets |
|
· |
Quoted prices for identical or similar assets or liabilities in markets that are not active |
|
· |
Observable inputs other than quoted prices that are used in the valuation of the assets or liabilities (i.e., interest rate and yield curve quotes at commonly quoted intervals) |
|
· |
Inputs that are derived principally from or corroborated by observable market data by correlation or other means. |
Level 3 – Unobservable inputs for the asset
or liability (i.e., supported by little or no market activity). Level 3 inputs include management’s own assumption about the assumptions
that market participants would use in pricing the asset or liability (including assumptions about risk).
The level in the fair value hierarchy within which
the fair value measurement is classified is determined based upon the lowest level of input that is significant to the fair value measurement
in its entirety.
Certain of the Company’s financial instruments
are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid
or short-term nature, such as cash and cash equivalents, accounts payable and accrued expenses and notes payable.
The carrying value of our contingent liability approximated
the fair value as of May 31, 2022 in considering Level 1 inputs within the hierarchy.
The following tables set forth by level, within the fair value hierarchy,
the Company’s financial instruments carried at fair value as of May 31, 2022 and May 31, 2021:
|
|
May 31, 2022 |
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
Contingent liability |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Derivative liability |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Total |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
May 31, 2021 |
|
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
Contingent liability |
|
$ |
415,227 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
415,227 |
|
Derivative liability |
|
|
— |
|
|
|
— |
|
|
|
110,588 |
|
|
|
110,588 |
|
Total |
|
$ |
415,227 |
|
|
$ |
— |
|
|
$ |
110,588 |
|
|
$ |
525,815 |
|
F-14
Note 5 – CARECLIX ACQUISITION
On December 17, 2021, the Company entered
into a Stock Purchase Agreement (“SPA”) with CareClix Holdings, Inc., a Florida corporation (“SOLI”) to acquire
four operating subsidiaries of SOLI. On December 31, 2021, under the terms of a Management Operating Agreement, the Company agreed to
conditional partial closing of the transaction set forth in the SPA (the “Interim Closing”) with the final closing conditioned
on the effectiveness of a registration statement to be filed by the Company with the SEC for the common shares to be issued as the consideration
for the acquisition. The Management Operating Agreement provided that if the registration statement was not filed by the Company and effective
by May 31, 2022, the Interim Closing would be rescinded, and the CareClix Group would not be part of the Company.
On May 2, 2022, the Company adopted
an Amended Management Agreement which allowed the Final Closing of the acquisition, with the remaining unpaid stock consideration reflected
as a liability and the May 31, 2022 transaction drop dead date thereby extended. On September 15, 2022, former management filed an action
to restore themselves as directors, to rescind the Amended Management Operating Agreement and to terminate the CareClix Companies’
acquisition. Current management agreed, the Amended Management Operating Agreement of May 2, 2022 has been rescinded as of May 2, 2022,
and the drop dead date became effective. Accordingly, the CareClix Companies are not part of the Company. and the Company has no continuing
claim under the transaction agreements.
F-15
Note 6 – SMARTAXIOM, INC. ACQUISITION AND DISPOSAL
On April 16, 2021, the Company entered into
a stock purchase agreement with SmartAxiom, Inc. (“SA”) and its shareholders providing for the Company to purchase of all
the outstanding common stock shares of SA. The Agreement was supplemented by First and Second Addendum Agreements, dated April 30, 2021,
and May 11, 2021, respectively.
The SA Acquisition Agreement and the First
and Second addendum agreements provide for the purchase of 100% of the SA’s issued and outstanding shares, providing for the Company’s
acquisition of SA with consideration consisting of 13,000,000 shares of the Company’s common stock; 210,000 shares of the Company’s
new Series D Convertible Preferred Shares, convertible, over an eighteen month earn out schedule, into our common stock shares with a
floor price of twenty cents, and an earn-out, as defined, by SA to be paid in our common stock. The SA Agreement also specifies that the
liabilities acquired by the Company will be limited to $75,000. We will also provide an additional $2,000,000 in working capital from
the public or private markets by no later than 18 months from the close of the SA Acquisition. On May 11, 2021, we closed on the SA Acquisition.
The following table summarizes the purchase price as of May 11,
2021, the date of acquisition:
|
|
|
|
|
Issuance of 13,000,000 shares of the Company’s common stock per share |
|
$ |
2,730,000 |
|
Issuance of 210,000 Series 'D" Preferred convertible stock, each share is convertible into 10 common shares |
|
|
203,613 |
|
A maximum of $2,200,000 of LFER common shares to be issued, subject to an earn-out, as defined, by SA over 18 month period from closing date of the acquisition. |
|
|
2,221,777 |
|
Excess of SA liabilities over the $75,000 acquired by the Company |
|
|
(111,263 |
) |
Total purchase consideration |
|
$ |
5,044,127 |
|
The following table summarizes the allocation of the purchase
price to the fair values of the assets acquired and liabilities assumed on May 11, 2021, the date of acquisition:
|
|
|
|
|
Cash |
|
$ |
39,878 |
|
Accounts receivable, net of an allowance for doubtful account of $7,554 |
|
|
5,802 |
|
Prepaid expenses and other current assets |
|
|
3,375 |
|
Furniture and fixture, net |
|
|
3,687 |
|
Intangible assets - Capitalized software development costs, patents, customer lists net of accumulated amortization of 98,630; |
|
|
5,177,643 |
|
Accounts payable and accrued expenses |
|
|
(73,533 |
) |
Line of credit |
|
|
(23,406 |
) |
Notes payable |
|
|
(89,319 |
) |
Total purchase consideration |
|
$ |
5,044,127 |
|
On March 8, 2022, we executed a Stock Purchase and
Mutual Release Agreement (the “Agreement”) under which we divested our ownership of SA, effective December 31, 2021. Under
the Agreement, we agreed to transfer all ownership in SA to Amit Biyani, the CEO of SA, in exchange for Mr. Biyani’s agreement to
return for cancellation: (ii) 7,974,695 shares of common stock; and (ii) 128,822 shares of
Series D Preferred Stock. In addition, SA and Mr. Biyani agreed to arrange for the return and cancellation of the remaining outstanding
64,942 shares of Series D Preferred Stock currently held by other former shareholders of SA. By agreement among the parties, the divestiture
of SA was deemed legally effective as of December 31, 2021. The Agreement also contained mutual releases amongst the parties.
F-16
In connection with the Agreement, SA issued to the
Company an 8% Unsecured Convertible Note in the amount of $250,000 dated December 31, 2021 (the “Note”). The Note bears interest
at a rate of 8 percent per year, with all principal and interest due on or before February 28, 2024. All unpaid principal and interest
owing under the Note may, at the Company’s option, be converted in whole into a number of fully paid and non-assessable shares of
common stock of SA having a value equal to the Note balance, converted at an assumed total valuation of SA of $6,250,000 on a fully diluted
basis. The following table summarizes the disposition of the SA subsidiary:
Net assets sold |
|
$ |
1,669,584 |
|
Sales Price |
|
$ |
534,305 |
|
Loss from sale of Subsidiary |
|
$ |
1,135,279 |
|
Note 7 – DISCONTINUED OPERATIONS
During the year ended May 31, 2021, the Company discontinued
the wholesale beverage distribution operations, and the Company announced its intention divest away from its business as a Consumer-Packaged
Goods (“CPG”) Company. The following table details of the Company’s discontinued operations for the years ended May
31, 2022, and 2021:
|
|
2022 |
|
2021 |
LFER |
|
$ |
— |
|
|
|
25,135 |
|
SA |
|
|
1,221,091 |
|
|
$ |
— |
|
VK |
|
|
— |
|
|
|
— |
|
JCG |
|
|
|
|
|
|
— |
|
|
|
$ |
1,221,091 |
|
|
$ |
25,135 |
|
Note 8 – INTANGIBLE ASSETS
Intangible assets as of May 31, 2022 and 2021 were
as follows:
|
|
May 31, 2022 |
|
May 31, 2021 |
Intangible assets to be amortized: |
|
|
|
|
Beginning Balance |
|
$ |
5,181,272 |
|
|
$ |
— |
|
|
|
|
|
|
|
Brand recognition, business relationships and customer lists, software development, patents, business relationships and customer lists acquired from SA |
|
|
|
|
|
|
5,181,272 |
|
|
|
|
|
|
|
Capitalized software costs |
|
|
189,393 |
|
|
|
|
|
|
|
|
|
|
|
Less: accumulated amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets to be amortized: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Brand recognition, business relationships and customer lists, software development, patents, business relationships and customer lists acquired from SA |
|
|
(709,740 |
) |
|
|
79,272 |
|
|
|
|
|
|
|
Less: SA net intangible assets disposed |
|
|
(4,660,925 |
) |
|
|
|
|
|
|
|
|
|
|
Less: Impairment |
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
Net book value at the end of period |
|
$ |
0 |
|
|
$ |
5,181,272 |
|
|
|
|
|
|
|
The Company amortizes its intangible assets
using the straight-line method over a 5 year period. The Company reviews its intangible assets when there are indications of performance
issues.
Amortization expense for the years ended May 31, 2022
and 2021 was $0 and $79,272, respectively.
F-17
Note 9 – NOTES PAYABLE – RELATED
PARTIES
On January 23, 2019, ESD issued a demand note
in the amount of $10,000 to a related party. The note is unsecured, bears interest at an annual rate of 20% and had an original maturity
date of March 1, 2019. On March 12, 2019, the obligations due under the terms of the note were assigned to the Company. The maturity date
on the note had been extended to March 1, 2020. During years ended May 31, 2021 and 2020, the Company recorded interest expense of $2,000
and $2,000, respectively, and accrued interest on the note at May 31, 2020 amounted to $4,707.
On January 28, 2020, the Company issued a demand note
in the amount of $8,200 to a related party. The note is unsecured, bears interest at an annual rate of 20% and has maturity date of January
28, 2021. During the years ended May 31, 2021 and 2020, the Company recorded interest expense of $1,640 and $557, respectively.
Prior to ESD’s bankruptcy declaration, ESD became
indebted to certain creditors in the total amount of $45,169 which indebtedness was personally guaranteed by Fernando Leonzo, the Company’s
CEO. The debt was not protected under the ESD bankruptcy. On February 20, 2020, the Company and Fernando Leonzo entered into an agreement
under which Fernando Leonzo would discharge the indebtedness personally and directly and the Company would pay Fernando Leonzo, $3,000
per month beginning February 2020 until such time that the indebtedness is fully discharged. Interest will accrue at an annual rate of
5% on any monthly payments not made by the 21st of the month. As of May 31, 2021, the Company paid a total of $14,300
to Fernando Leonzo in accordance with this agreement. During the years ended May 31, 2021 and 2020, the Company recorded interest expense
of $1,991 and $527, respectively.
The following table summarizes the Company’s
Note Payable – Related Parties as of May 31, 2022:
Issue Date |
|
Maturity Date |
|
Interest Rate |
|
Original Amount |
|
Accumulated Payments as of May 31, 2022 |
|
Accumulated Accrued interest on Note |
|
Conversion into Common & Preferred C shares |
|
Unamortized Deferred Financing Costs as of May 31, 2022 |
|
Balance May 31, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1/23/2019 |
|
3/1/2020 |
|
|
20 |
% |
|
$ |
10,000 |
|
|
$ |
— |
|
|
$ |
5,419 |
|
|
$ |
(15,419 |
) |
|
|
|
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1/28/2020 |
|
1/28/2021 |
|
|
20 |
% |
|
$ |
8,200 |
|
|
$ |
— |
|
|
$ |
2,781 |
|
|
$ |
(10,981 |
) |
|
|
|
|
|
$ |
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/20/2020 |
|
2/19/2021 |
|
|
5 |
% |
|
$ |
45,169 |
|
|
$ |
16,550 |
|
|
$ |
4,135 |
|
|
|
|
|
|
|
|
|
|
$ |
32,755 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6/15/2021 |
|
6/29/2021 |
|
|
8 |
% |
|
$ |
60,976 |
|
|
$ |
— |
|
|
$ |
4,678 |
|
|
|
|
|
|
|
|
|
|
$ |
65,653 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10/6/2021 |
|
10/6/2022 |
|
|
10 |
% |
|
$ |
10,000 |
|
|
$ |
— |
|
|
$ |
649 |
|
|
|
|
|
|
$ |
6,157 |
|
|
$ |
4,492 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10/6/2021 |
|
10/6/2022 |
|
|
10 |
% |
|
$ |
7,500 |
|
|
$ |
— |
|
|
$ |
487 |
|
|
|
|
|
|
$ |
6,157 |
|
|
$ |
1,830 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11/10/2021 |
|
11/10/2022 |
|
|
10 |
% |
|
$ |
10,000 |
|
|
$ |
— |
|
|
$ |
553 |
|
|
|
|
|
|
$ |
3,208 |
|
|
$ |
7,345 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
10,502 |
|
|
|
|
|
|
$ |
15,522 |
|
|
$ |
112,076 |
|
The following table summarizes the Company’s
Note Payable – Related Parties as of May 31, 2021:
Issue Date |
|
Maturity Date |
|
Interest Rate |
|
Original Amount |
|
Accumulated Payments as of May 31, 2021 |
|
Accumulated Accrued interest as of May 31, 2021 |
|
Balance May 31, 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
1/23/2019 |
|
3/1/2020 |
|
|
20 |
% |
|
$ |
10,000 |
|
|
$ |
— |
|
|
$ |
4,707 |
|
|
$ |
14,707 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1/28/2020 |
|
1/28/2021 |
|
|
20 |
% |
|
$ |
8,200 |
|
|
$ |
— |
|
|
$ |
2,197 |
|
|
$ |
10,397 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2/20/2020 |
|
2/19/2021 |
|
|
5 |
% |
|
$ |
45,169 |
|
|
$ |
14,300 |
|
|
$ |
2,518 |
|
|
$ |
33,387 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
58,491 |
|
F-18
Notes payable to related parties are recorded on our
consolidated balance sheets net of unamortized deferred financing costs of $15,522 and $0 as of May 31, 2022 and May 31, 2021, respectively.
Note 10 – NOTES PAYABLE
On September 15, 2020, the Company issued a Note in
the principal amount of $30,000 which had a maturity date of December 15, 2020. The Note was note not repaid by the maturity date and
thus bears interest at an annual rate of 6% from the date of maturity. During years ended May 31, 2022 and 2021, the Company recorded
interest expense of $2,100 and $528, respectively.
As of May 31, 2022, future principal payments of the
notes payable were as follows:
For the twelve months ending May 31,
2023
Note 11 – NOTES PAYABLE - DUE CARECLIX, INC.
During the period beginning from December 6, 2021
through May 31, 2022, the Company issued seven (7) Notes Payable to CareClix, Inc. with total principal amounts aggregating to $105,933.
Each note matures one year from the issuance date and bears interest at an annual rate of 6% from the date issued. During years ended
May 31, 2022 and 2021, the Company recorded interest expense of $2,325 and $0, respectively.
As of May 31, 2022, future principal and interest
payments of the seven (7) Notes Payable were as follows:
For the twelve months ending May 31,
2023
Note 12– CONVERTIBLE NOTES PAYABLE
|
|
May 31, 2022 |
|
May 31, 2021 |
|
|
Unamortized deferred finance costs and original issue discount |
|
Principal |
|
Net |
|
Unamortized deferred finance costs and original issue discount |
|
Principal |
|
Net |
2017 NPA Notes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
737,500 |
|
|
$ |
737,500 |
|
The 2nd Note Offering |
|
|
|
|
|
$ |
27,002 |
|
|
$ |
27,002 |
|
|
|
|
|
|
|
280,000 |
|
|
|
280,000 |
|
2022 Note Issuances |
|
$ |
6,157 |
|
|
|
55,000 |
|
|
|
48,843 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
2021 Note Issuances |
|
|
— |
|
|
|
77,000 |
|
|
|
77,000 |
|
|
$ |
29,633 |
|
|
|
77,000 |
|
|
|
47,367 |
|
2020 Note Issuances |
|
|
— |
|
|
|
45,330 |
|
|
|
45,330 |
|
|
|
— |
|
|
|
275,500 |
|
|
|
275,500 |
|
2019 Note Issuances |
|
|
— |
|
|
|
351,348 |
|
|
|
351,348 |
|
|
|
— |
|
|
|
482,597 |
|
|
|
482,597 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
6,157 |
|
|
$ |
555,680 |
|
|
$ |
549,523 |
|
|
$ |
29,633 |
|
|
$ |
1,852,597 |
|
|
$ |
1,822,964 |
|
F-19
As of May 31, 2022, 10 convertible notes with principal
amounts aggregating $655,681 have passed their maturity date.
If all convertible notes are converted into common
stock, approximately a total of 2,300,000 common shares would be issued.
Note 13– NOTE PAYABLE L&H, Inc.
On December 14, 2020, the Company received a Complaint
from a note holder, L & H, Inc. (“L&H”), filed in the First Judicial District Court of Nevada, Carson City, alleging
breaches of contract regarding the Company’s failure to repay amounts due or failing to issuing shares upon demand and breach of
Implied covenant of good faith and fair dealing in connection with the $110,000 September 10, 2019 Convertible Promissory Note between
L&H and the Company. On May 26, 2022, the Court entered judgment against us in the total amount of $171,116, including the principal
sum, accrued interest, default interest of $44,428. attorney’s fees of $10,000 and $1,127 in costs.
During years ended May 31, 2022 and 2021, the Company
recorded interest expense on the L&H Note Payable of $55,112 and $31,850, respectively.
As of May 31, 2022, future principal payments of the
L&H Note Payable note payable were as follows:
For the twelve months ending May 31,
2023
Note 14– CAPITAL STOCK
As of May 31, 2022, the authorized capital stock of
the Company was 500,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value
per share.
Common Stock. On May 31, 2022, there were 71,822,753
common shares issued. The Board of Directors, when increased to a majority independent Board, will review certain issues of stock to former
management, which may result in changes to the issued shares.
During the year ended May 31, 2022, and May 31, 2021,
the Company issued 2,581,592 and 368,593 shares, respectively, in exchange for financing and services provided by select individuals and
or vendors. The shares were issued at prices ranging from $0.07 to $0.156 per share.
Also, on February 4, 2022, the Company issued shares
of common stock and Series C preferred shares to former members of the Board of Directors at par value in exchange for services provided.
The following table summarizes the shares issued to the members of the Board of Directors. The difference between the fair value of the
shares acquired and the acquisition price has been recognized as officers’ compensation in the statement of operations for the year
ended May 31, 2022.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common
Stock |
|
Series C
Preferred |
|
Consideration
Shares |
|
Common
Stock |
|
Series C
Preferred |
|
Consideration
Shares |
|
Common
Stock |
|
Series C
Preferred |
|
Consideration
Shares |
|
Total |
Robert Gunther |
|
|
2,678,672 |
|
|
|
327,393 |
|
|
|
654,786 |
|
|
$ |
2,678 |
|
|
$ |
327 |
|
|
$ |
— |
|
|
$ |
204,115 |
|
|
$ |
327,066 |
|
|
$ |
50,549 |
|
|
$ |
581,731 |
|
Juan Romagossa |
|
|
2,815,279 |
|
|
|
344,090 |
|
|
|
688,180 |
|
|
$ |
2,815 |
|
|
$ |
344 |
|
|
$ |
— |
|
|
$ |
214,525 |
|
|
$ |
343,746 |
|
|
$ |
53,127 |
|
|
$ |
611,398 |
|
Fernando Leonzo |
|
|
3,019,602 |
|
|
|
369,062 |
|
|
|
738,124 |
|
|
$ |
3,020 |
|
|
$ |
369 |
|
|
$ |
— |
|
|
$ |
230,093 |
|
|
$ |
368,693 |
|
|
$ |
56,983 |
|
|
$ |
655,769 |
|
Mahmood Kahn |
|
|
3,989,624 |
|
|
|
487,621 |
|
|
|
975,242 |
|
|
$ |
3,990 |
|
|
$ |
486 |
|
|
$ |
— |
|
|
$ |
304,009 |
|
|
$ |
487,135 |
|
|
$ |
75,289 |
|
|
$ |
866,433 |
|
|
|
|
12,503,177 |
|
|
|
1,528,166 |
|
|
|
3,056,332 |
|
|
$ |
12,503 |
|
|
$ |
1,526 |
|
|
$ |
— |
|
|
$ |
952,742 |
|
|
$ |
1,526,640 |
|
|
$ |
235,949 |
|
|
$ |
2,715,331 |
|
Preferred Stock
As of May 31, 2022, the Company had four designated
classes of preferred stock authorized: Series A Preferred, Series B Preferred, Series C Preferred and Series D Preferred. As of May 31,
2022, the following preferred shares were issued:
F-20
Series A Preferred Stock
The Company has designated 5,200,000 shares
of Series C Preferred Stock, par value $0.001 per share. As of May 31, 2021, 5,200,000 shares were issued and outstanding. A total of
4 million shares of Series A Preferred Stock were issued to Charles O. Scott as part of the acquisition of the CareClix Group of companies.
The other outstanding Series C Preferred shares were cancelled and reissued to Mr. Scott as part of the acquisition of the CareClix Group
of companies. Mr. Scott currently holds 5,200,000 shares representing all of the issued and outstanding Series A Preferred stock.
The Series A Preferred Stock has the equivalent voting
rights as 60 shares of common stock. The Series A Preferred Shares do not have liquidation preferences and do not pay dividends.
Series B Preferred Stock
The Company has designated 100,000 shares
of Series B Preferred Stock, par value $0.001 per share. As of May 31, 2021, there were 100,000 shares of Series B Preferred stock issued,
held by three holders of record.
Holders of Series B Preferred Shares have no voting
rights, have the right to convert their Series B Preferred Shares into Common Stock shares; and have a 10% annual cash dividend paid quarterly.
Series C Preferred Stock
The Company has designated 2,393,375 shares
of Series C Preferred Stock, par value $0.001 per share. As of May 31, 2021
A total of 2,393,375 Series C Preferred shares were
issued in the year ended May 31, 2022, all of which were issued at $1.00 per shares except for the shares issued to former management,
which were issued at $0.001 per share to former directors and are considered validly issued and outstanding only to the extent of actual
cash paid, at a purchase price of $1.00 per share. On January 14, 2022, 50,000 Series C Preferred shares were converted into 525,000 common
shares. During June 2022, 20,000 Series C Preferred shares were cancelled.
The Series C Preferred Stock does not have
liquidation preferences. The Series C Preferred Stock has no voting rights except to the extent that they hold Common Stock Shares from
conversion, in which case each Common Stock share will be equal to one vote. The Company shall pay the holders of Series C Preferred Stock
a 10% annual cash dividend paid quarterly.
Series D Preferred Stock
The Company has designated 16,236 shares of Series
D Preferred Stock, par value $0.001 per share. On of May 31, 2022, 16,236 shares of our Series D Preferred Stock are issued and outstanding.
During 2022, a total of 193,764 shares of Series D. Preferred shares were cancelled as part of the transfer of SmartAxiom back to its
original shareholders.
The Series D Preferred Stock does not have
liquidation preferences. The Series D Preferred Stock has no voting rights except to the extent that they hold Common Stock Shares from
conversion, in which case each Common Stock share will be equal to one vote. Each share of the Series D preferred stock converts into
10 shares of the Company’s common stock. The Series D Preferred Stock pays no dividend.
Warrants
None at May 31, 2022.
Note 15 - COMMITMENTS AND CONTINGENCIES
On October 21, 2021, a judgment was entered against
the Company and in favor of a former employee. Under the terms of the judgment, the Company is required to (i) pay the former employee
a total of $60,000 of scheduled payments, (ii) issue the former employee 500,000 shares of the Company’s common stock at $0.10 per
share and, (iii) pay legal fees of up to $8,923 in scheduled payment to the former employee’s attorney. The 500,000 shares of the
Company’s common stock were issued to the former employee on October 21, 2021 and as of May 31, 2022, the Company is current in
payments with respect to the judgment.
On March 16, 2021, we received a complaint filed by
Anshu Sharma and Aditya Sharma against the Company and the Company's officers/directors in the County of Hennepin, Minnesota (District
Court; Fourth Judicial District) in connection with our agreement regarding an investment by the Plaintiffs in our Preferred C Shares.
On March 29, 2021, we filed “Defendant’s Joint Motion to Dismiss” to dismiss the complaint. The Company believes that
there is no merit to the complaint, and it intends to vigorously defend this matter. On February 22, 2022 the Court dismissed the case.
F-21
Note 16 - INCOME TAXES
The deferred tax attributes consist of the following:
|
|
May 31, 2022 |
|
May 31, 2021 |
Net operating loss carryforward |
|
$ |
5,987,000 |
|
|
$ |
4,743,000 |
|
Stock based compensation |
|
|
1,392,000 |
|
|
|
1,327,000 |
|
Valuation allowance |
|
|
(7,379,000 |
) |
|
|
(6,070,000 |
) |
Deferred tax asset, net |
|
$ |
— |
|
|
$ |
— |
|
For the year ended May 31, 2022, the valuation allowance
increased by approximately $1,309,000.
On December 22, 2017, the enactment date, the Tax
Cuts and Jobs Act (“Act”) was signed into law. The Act enduringly reduces the top corporate tax rate from 35 percent to a
flat 21 percent beginning January 1, 2018 and eliminates the corporate Alternative Minimum Tax. The Company has adjusted its deferred
tax calculations to reflect this reduction in its tax rate.
The deferred tax asset differs from the amount computed
by applying the statutory federal and state income tax rates to the loss before income taxes. The sources and tax effects of the differences
are as follows:
As of May 31, 2022, the Company has net operating
loss carryforwards of approximately $21,000,000 to reduce future federal and state taxable income.
The Company currently has no federal or state tax
examinations in progress, nor has it had any federal or state examinations since its inception. All of the Company’s tax years are
subject to federal and state tax examinations
Note 17 - RELATED PARTY TRANSACTIONS
There are no significant related party transactions
except for the transactions engaged in by former management. See Item 9 (B) in this Report.
Note 18 – SUBSEQUENT EVENTS
None, other than termination of the CareClix Companies
acquisition as a result of the action filed by former management, as previously discussed and the failure of consideration.
F-22
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
Financial Statement Schedules
The financial statements of Life On Earth, Inc. are
listed on the Index to Financial Statements on this annual report on Form 10-K beginning on page F-1.
Exhibits
The following Exhibits are being filed with this Annual
Report on Form 10-K:
|
3.1 |
|
|
Articles of Incorporation as amended, incorporated by reference to Form 8-K, Exhibit 3.1 filed May 6, 2022 |
|
3.2 |
|
|
Amended Statement of Preferences for Series A Preferred, incorporated by reference to Form 8-K, Exhibit 3.2 filed May 6, 2022 |
|
3.3 |
|
|
Amended Statement of Preferences for Series C Preferred, incorporated by reference to Form 8-K, Exhibit 3.3 filed May 6, 2022 |
|
31.1 |
|
|
Certification of Chief Executive Officer pursuant to SEC Rules 13a-14a and 15d-14a adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
31.2 |
|
|
Certification of Principal Accounting Officer pursuant to SEC Rules 13a-14a and 15d-14a adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
32.1 |
|
|
Certification of Chief Executive Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
SIGNATURES
Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
|
LIFE ON EARTH, INC. |
|
|
|
|
Dated: September 23, 2022 |
By: |
/s/ Charles Scott |
|
|
|
Charles Scott
Chief Executive Officer and Board of Director
(Principal Executive Officer) |
|
|
|
|
|
Dated: September 23, 2022 |
By: |
/s/ Jeffry Hollis |
|
|
|
Jeffry Hollis
Controller
(Principal Accounting Officer) |
|
In accordance with the Exchange
Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
____/s/ Charles Scott
Chairman and Director
Date: September 23, 2022
____/s/ S. John Korangy
President and Director
Date: September 23, 2022
23
v3.22.2.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
This regulatory filing also includes additional resources:
exhibit_10-1.pdf
Life on Earth (CE) (USOTC:LFER)
Historical Stock Chart
From May 2024 to Jun 2024
Life on Earth (CE) (USOTC:LFER)
Historical Stock Chart
From Jun 2023 to Jun 2024